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Target identification and mechanism of action studies of plant-derived 
compounds play a critical role in drug discovery. The knowledge of the 
bioactivity of natural compounds can lead to a number of advantages: first of 
all, it is possible to understand their full therapeutic potential; in addition, it 
can allow the further identification of their side-effects, their toxicity and also 
structure-activity relationships studies. 
This research project is focused on a Reverse Chemical Genetics approach,
 
which relies on the screening of libraries of plant small molecules (provided 
by the Department of Pharmacy (DIFARMA)-Bioactive Natural Products,  
University of Salerno (UNISA), Fisciano, Italy) able to bind specific target 
proteins and on the validation of the ligand/protein interaction. In my PhD 
project I focused on three protein targets, over-expressed in cancer and 
identified as potential markers in several tumor cell lines: Nucleolin, Heat 
Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90).    
Nucleolin (NCL) is a multifunctional protein involved in many process such 
as DNA transcription, ribosome biogenesis and regulation of mRNAs of anti-
apoptotic and antiproliferative proteins such as AKT1, Bcl2, p53. Firstly, a 
screening of ent-kaurane and ent-trachilobane library by Cellular Thermal 
Shift Assay (CETSA) on Jurkat (leukemia T cells) and HeLa (cervical 
carcinoma) was performed, obtaining as main ligand of Nucleolin the 6,19-
dihydroxy-ent-trachiloban-17-oic acid (12) from Psiadia punctulata ((Vatke) 
Asteraceae). Full length Nucleolin/12 interaction was validated in HeLa 
(cervical carcinoma) cells by CETSA and Drug Affinity Responsive Target 
Stability (DARTS). Nucleolin RNA Binding Domains 1-2/12 interaction was 
investigated by Saturation Transfer Difference NMR (STD-NMR), 
WaterLOGSY and Surface Plasmon Resonance (SPR): no interaction  was 
 
 
observed with these two domains of the protein. The mechanism of action of 
the selected diterpene was studied by Flow Cytometry (sub G0/G1 cell cycle 
arrest), WB analysis (reduction of intracellular AKT1 and Bcl2 levels and 
pNCL levels on the cell membrane), RTq-PCR (reduction of AKT1 and Bcl2 
mRNAs), MTT (IC50: 20 ± 1 µM), Protein Synthesis and Wound Healing 
assays in HeLa cells (reduction of 20% of migration). Therefore, the 6,19-
dihydroxy-ent-trachiloban-17-oic acid (12) may be considered as a new 
promising modulator of Nucleolin.    
The second target protein was the molecular chaperon Heat Shock Protein 70 
(Hsp70). A diterpene library was screened by SPR assay, in order to select 
putative Hsp70 ligands. SPR results showed that the ent-7β-acetoxy,18-
hydroxy-15α,16α-epoxikaurane (epoxysiderol or compound 27) from Sideritis 
spp (Lamiaceae)  interacts with Hsp70 (KD: 54 ± 1.2 nM). Epoxysiderol  
ability to modulate Hsp70 activity was assessed through MS (no covalent 
binding), DARTS and WB experiments. Moreover, epoxysiderol was tested 
on HeLa cells by MTT (IC50: 20 ± 0.9 µM), Flow Cytometry (G2/M and 
subG0/G1 cell cycle arrest), WB for its effect on the intracellular levels of  
Hsp70, Hsp90, and Hsp70 client proteins (reduction of pAKT1, p-p38 and p-
JNK1) in HeLa cells, and by WB also for Hsp70 cytosolic and cell membrane 
levels (reduction of Hsp70 levels). Finally, ATPase assay (50% of reduction in 
dose-dependent manner) and molecular docking studies (interaction with the 
Hsp70 Nucleolide Binding Domain) were carried out. Therefore, in this study 
epoxysiderol was identified as a new Hsp70 inhibitor through cell-free and 
cell-based assays.    
Another target object of study in this PhD project was the Heat Shock 
Protein 90 (Hsp90). Fusicoccane diterpenes from  Hypoestes forsskaolii 
((Vahl) Acanthaceae), abietane diterpenes form Zhumeria majdae ((Rech.f. & 
Wendelbo)  Lamiaceae) and from different Salvia spp (Lamiaceae) were 
 
 
screened against Hsp90 by SPR and by MTT in HeLa, Jurkat and MCF7 cells, 
selecting the 18-hydroxyhypoestenone (6) and lanugon Q (20) as Hsp90 
ligands. Subsequently,  MTT assay was performed to investigate their 
cytotoxic and anti-proliferative activity: 18-hydroxyhypoestenone was the 
most cytotoxic in HeLa cells (IC50: 18 ±1 µM), whereas lanugon Q showed 
higher activity towards MCF7 (IC50: 20 ± 2 µM). In addition, Flow Cytometry 
and WB analyses were carried out: G2/M cell cycle arrest and reduction of p-
Cdc2, pAKT1 and pERK1 levels were observed in HeLa cells after treatment 
with 6 (10 µM and 20 µM for 48h); Decrease of pERK, pAKT, cyclin A was 
observed in MCF7 after 48h of treatment with 20 (18 µM). Selected 
diterpenes were also tested against Hsp90 by ATPase activity assay: dose-
dependent reduction (40%) of hydrolysis was observed with compound 6 (1,5, 
10 µM), while no inhibition was induced by 20. Furthermore, molecular 
docking studies were implemented with compound 6, and the computational 
analysis of the Hsp90/6 interaction suggested a C-terminal domain. In 
conclusion, in this study 18-hydroxyhypoestenone and lanugon Q were 
identified as new Hsp90 interactors, able to modulate its activity and its client 

















































































































1.1 Plant small molecules  in drug discovery and development  
Natural compounds play a crucial role in drug discovery and drug 
development. This is particularly evident in the areas of cancer and infection 
diseases, whereas over 60% and 75% of therapeutic agents have to be 
considered of natural origin. This contribution seems impressive, but it can be 
easily explained in the light of the chemical and evolutionistic proprieties 
shown by natural products. First of all, they exhibit a wide range of 
pharmacophores and a high degree of stereochemistry. Therefore, they have 
been - and they are still - an invaluable source of inspiration for organic 
chemist to synthesize novel drug candidates,
1
 since they provide a new starting 
point for new synthetic compounds with diverse structures and often with 
multiple stereocenters that can be challenging synthetically. Indeed, many 
structural features common to natural products (e.g., chiral center, aromatic 
rings, complex ring system, degree of molecule saturation and number and 
ratio of heteroatoms) are expected to contribute to the ability of natural 
products to provide hits even against the more difficult screening targets, such 
as protein-protein interactions.
2
 Moreover, they may have the additional 
advantage of being natural molecules: compounds that are efficient as drugs 
have been suggested to have the propriety of ‗metabolite-likness‘.
3
 Therefore, 
natural compounds are a good starting point for the setting up of libraries to 
test for drug discovery, not only for their complex and diversified chemical 
space but also for their ability to interact with biomolecules. 
Although natural products have not been developed to bind to human proteins, 
they can do it. There are two main theories to explain this phenomenon: the 
first, widely accepted, is based on their ability to bind human proteins as a 
4 
 
result of a long-term co-evolution within biological communities; interacting 
organisms, that evolved in close proximity to one another, developed 
compounds that could influence the biological process of neighboring species.4 
The second theory, advanced by Howitz and Sinclair and called xenohormesis, 
(Fig. 1) is based on the hypothesis that there have been common ancestors of 
plants and animals able to synthesize a large number of stress- induced 
secondary metabolites; animals and fungi, that feed on plants, gradually lost 
the capacity to synthesize these low-weight molecular compounds while plants 
retained this ability. Animals and fungi only retained the ability to sense these 
chemical cues in plants, possibly in order to detect when plants were stressed 




Figure 1. Xenohormesis hypothesis. Sirtuin enzymes evolved early in life‘s history to increase 
somatic maintenance and survival during times of adversity. The xenohormesis hypothesis of 
Howitz and Sinclair proposes that primordial species synthesized polyphenolic molecules to 
stimulate sirtuins during times of stress. Only plants have retained this ability. Survival 
pathways in fungi and animals, instead, have retained the ability to respond to plant stress 
signalling molecules because they provide useful prediction about the state of the environment 
and/or food supply. This ability would allow organisms to prepare for and survive adversity 






In fact, natural products are evolutionary preselected, owning structural 
requirements to be bound to proteins. Their structural scaffolds represent the 
biologically relevant fractions of chemical space explored by nature so far.
6
 
Moreover, recently Stuart Schreiber, Paul Clemons and their colleagues at the 
Broad Institute in Boston, performed a bioinformatic analysis of natural 
product targets, thus demonstrating that natural molecules statically tend to 
target proteins with a high number of protein–protein interactions that are 
particularly essential for an organism.
7
 This observation is consistent with the 
common role played by natural products as chemical weapons against 
predators or competitors. 
The long-lasting experience of traditional folk medicines may facilitate the 
identification of novel agents. Although in industrialized countries medicinal 
herbs gradually lost importance, replaced by the chemical progress during the 
20
th
 century, bioactive plant compounds are recently experiencing an 
impressing revival.  
The plant world possesses an uncountable number of specialized metabolites, 
characterized by different chemical scaffolds and a wide range of biological 
properties such as protective agents against herbivores and various pathogens 
or growth regulators. The rationale in exploring plant-derived products relies 
on the assumption that their chemical scaffolds have been under a continuous 
co-evolutionary selection process to achieve interactions with biological 
macromolecules. Therefore, it is reasonable to assume that they might have 
more suitable structures to interact with cellular targets compared with 
chemicals.
8
 The use of plant small molecules to fight human diseases is a 
centuries old practice that has led to the discovery of more than half of the all 






Nowadays, researchers still focus on the identification and structural 
characterization of new plant compounds and on the discovery of their detailed 
mechanism of action.  To have an idea of the significance of the ethnobotanic 
use of plant drugs, it is sufficient just to consider the wide consumption of 




Despite the success of plant molecules as drugs and the large number of 
benefits they show, they are losing favor among drug developers. One reason 
is the perceived ―dirtiness‖ of plant molecules: a molecule is considered 
―dirty‖ if it interacts with numerous endogenous proteins. Such compounds 
presumably are more likely to have negative ―off target‖ effects than a 
molecule that specifically targets a single protein. Indeed, there are examples 
of plant molecules that, despite interacting with multiple human enzymes and 
receptors, are surprisingly safe:
11
 for example, salicylic acid, capsaicin or 
curcumin are surprisingly powerful and nontoxic, although they are multi-
target molecules. In fact, having multi-target molecules could be a winning 
strategy to face different diseases. It has been increasingly recognized that, in 
several pathologies, there is a large number of mutated genes and/or modified 
proteins that disrupt multiple pathways, which normally exhibit extensive 
biological cross-talk and redundancy. Therefore, the development of drugs that 
bind selectively to single protein targets also appears less clinically useful, 
since, interfering with a single target and/or pathway may not abrogate the 
disease. Moreover, a promising strategy for mitigating an acquired drug 
resistance or suppress disease, is to simultaneously inhibit multiple molecular 
pathways, either by using several agents in combination or by using a single 
agent that concurrently blocks multiple targets or pathways. 
Even if natural products enjoy a privileged position in drug discovery, they 
can exhibit multiple behaviors that could interfere in assay redouts, such as 
7 
 
metal chelation, redox cycling and protein reactivity. For these reasons several 
natural molecules were termed Pan Assay INterference compoundS (PAINS). 
12
 These compounds possess  reactive moieties, such as: 
- catechols (e.g. apomorphine, droxidopa): cathecols have a high propensity to 
be redox active and can also variously chelate metals as well as being reactive 
in the oxidized form to nucleophiles present in the side chain of proteins such 
as cysteine and lysine.  
- quinones (e.g. geldanamycin), because of the redox-active and reactive 
quinone moiety. 
- phenolic Mannich bases and hydroxyphenilhydrazones (e.g. topotecan, 
rifampicin).     
1.2  Terpenes 
Among the plant specialized metabolites, terpenes are an important class  
which constitute a vast family of natural substances structurally different from 
each other, whose starting elements for the biosynthesis are the isoprene units.  
They are produced by diverse organisms to perform an assortment of 
biological functions in varying ecological contexts and they are derived 
biosynthetically from units of isoprene (2-methyl-1,3-butadiene). Isoprene 
itself does not undergo the building process, whereas the activated forms, 
isopentenyl pyrophosphate (IPP or also isopentenyl diphosphate) and 
dimethylallyl pyrophosphate (DMAPP or also dimethylallyl diphosphate), are 
the actual components in the biosynthetic pathway (Fig. 2). There are two 
metabolic pathways that create terpenes: mevalonic acid pathway (MVA) and 
the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate 
pathway (MEP/DOXP pathway), also known as non-mevalonate pathway. In 
both MVA and MEP pathways, IPP is isomerized to DMAPP by the enzyme 
isopentenyl pyrophosphate isomerase. IPP and DMAPP condense to give 
8 
 
geranyl pyrophosphate, the precursor to monoterpenes and monoterpenoids. 
Geranyl pyrophosphate is also converted to farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate, respectively C15 and C20 precursors to 
sesquiterpenes and diterpenes (as well as sesequiterpenoids and 
diterpenoids).
13




Figure 2. Isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) 
condense to produce geranyl pyrophosphate, precursor to all terpenes and terpenoids.  
 
Although all terpenes are synthesized from two five-carbon building blocks, 
the structures and functions vary widely. Many terpenes have shown several 
biological activities. Isoprenoids and derivatives play a critical role in all 
living systems: the cell structure, systems of electron transport in cell-cell 
signals (steroids, abscisic acid, gibberellic acid, phytol ecc.), in the structure of 
organisms and interactions between them. Some isoprenoids play a role in 
plant defense systems against attack by micro-organisms and insects, act as 
allelopathic compounds in plant-insect and plant-environment.
15
 They are also 
used for the treatment of human diseases. In fact, there is a wide spectrum of 
bioactivities for these types of substances such as antibacterial, antifungal, 
antiparasitic, anti-inflammatory, cytotoxic and antitumor.
16
 Although they 
show all of these activities, approximately 35,000 terpenes have been 
9 
 
identified and the majority of the possible functions or biological activity of 
these molecules are unknown. Then, it would be interesting to study this class 
of natural molecules to find out its potential biological effects and uses in 
therapy. 
1.3  Diterpenes in cancer  
Among plant terpenes, diterpenes form a vast class of more than 10000 
structures (Fig.3). A number of potential anticancer diterpenes and their 
derivatives have been introduced already, such as taxanes (e.g. taxol and 
paclitaxel),
17,18




 diterpenes from 
coffee (e.g. cafestol, cafeic acid and kahweol) 
21









As we all know, cancers are considered one of the most lethal causes of death 
throughout the world.
22
 The use of medicinal preparations with plant-derived 
products is antique and, more recently, they have continued to enter in clinical 




In Figure 4 most of the known diterpenes involved in anti-cancer pathways 
such as oxidative stress, ER stress, proliferation/differentiation, autophagy, 
cell cycle arrest and apoptosis, are reported.  
 
Figure 4.  Anticancer pathways of diterpenes. 
 
Several diterpenes are reported to act in a number of cancer cells such as T 
leukemia (Jurkat), cervical carcinoma (HeLa), breast cancer (MCF7), human 
embryonic kidney (HEK293) cell lines, while either alone or combined to 
other diterpenes or anticancer drug, have been found to work synergistically. 
12 
 
Altogheter, we can conclude that diterpenes may be one of the leading 
therapeutic molecules in cancer.
24
 
1.4  Drug discovery today: Chemical Genetics 
Chemical genetics is an emerging field that can be used to study the 
interactions of chemical compounds, including natural products, with proteins. 
Chemical genetics uses chemical compounds, including plant molecules, that 
may modulate the activity of target proteins. 
24, 25
 This field comes from the 
classical genetics, widely used to study biology by manipulating the biological 
system at the level of the gene.  
Chemical Genetics offers several advantages over its classical counterpart and 
allows the study of unexplored biological space. For example, genes essential 
for survival or development cannot be studied using classical genetics; this can 
only be done using chemical genetics. Thus, the instantaneous effects of small 
molecules can be characterized using chemical genetics. It also makes it 
possible to study mammals whereas classical genetic techniques are more 
complicated to apply due to their diploid genome, physical size and slow 
reproduction rate.
26
 Other benefits of using chemical compounds are the 
temporal control and reversibility of the inhibition of protein function.
27
  
Classical genetics is divided into forward genetics (involving random 
mutations followed by phenotypic screening and gene identification) and 
reverse genetics (involving mutation of a specific gene and phenotype 
characterization). So, genetics in the ‗forward‘ direction is from phenotype to 
gene; in the ‗reverse‘ direction it is from gene to phenotype. As classical 
genetics, two approaches can be taken also to chemical genetics (Fig. 5): 







Figure 5. Chemical Genetics approaches: a) Forward chemical genetics;  
b) Reverse Chemical Genetics 
 
1) In FCG, typical random mutagenesis is replaced by a screening 
of a library of not targeted small molecules against multiple 
potential targets simultaneously. Compounds that induce a 
phenotype of interest can be selected and then the target 
protein of this compound is identified.
26
 Forward chemical 
genetics requires three components: a) a collection or library of 
small molecules; b) a biological assay with a quantifiable 
phenotypic output, usually performed using living cells or 
complex cellular extracts and c) a strategy to join an active 
compound to its biological target. Therefore, the last goal of 
FCG is the target identification.  
2) In RCG, a known target protein is screened using small 
molecule library to identify functional ligands that either 
stimulate or inhibit the target protein. Once a specific ligand 
that produces a change in the protein function is identified, it is 
introduced into a cell or organism and the resulting changes in 
14 
 
the phenotype are studied.
27
 Also RCG requires three 
components: a) specific protein target; b) a library of small 
molecules; c) cell-free or cell-based assays to validate the 
interaction and to understand the mechanism of action of the 
target bound to the ligand. Therefore, the goal of RCG is the 
validation of the interaction and of the protein target functions.   
1.5  Aim of the thesis 
This PhD project was mainly focused on a RCG approach,
 
starting from the 
screening of a library/collection of diterpenes able to bind a specific protein 
target. The molecules emerging from the screening were then studied to 
validate the screening results by cell-free and cell-based assays. In my PhD 
project were adopted:  
 Cell-based tecniques, such as: Cellular Thermal Shift Assay 
(CETSA), Drug Affinity Responsive Target Stability (DARTS), 
Western Blotting (WB), Flow Cytometry, RTq-PCR, Wound 
Healing, Apoptosis and  Protein Synthesis assays.  
 Cell-free tecniques, such as: Mass Spectrometry (MS), Surface 
Plasmon Resonance (SPR), Saturation transfer difference 
NMR (STD-NMR), WaterLOGSY and ATPase activity assays. 
 
1.6  Cell-free and cell-based assays 
 
a) Cellular Thermal Shift Assay (CETSA) 
CETSA allows to carry out qualitative and quantitative analyses of the direct 
interaction of a drug candidate to a target protein in the cells 
28
. In particular, 
this approach offers the opportunity to firmly link the observed phenotypic 
15 
 
response to a compound with a particular target engagement. CETSA, set up 
by Molina and coworkers in 2013, is based on the principle of thermodynamic 
stabilization inferred to the protein as a result of the ligand binding, which can 
be used for the estimation of binding free energies as well other 
thermodynamic properties for isolated systems at equilibrium. The shift in 
thermal stability is estimated by measuring the amount of remaining soluble 
target protein at different temperatures for treated and control samples. 
   CESTA protocol starts with the treatment of cells with either molecule of 
interest and vehicle as control, followed by cell heating (to denaturate and 
precipitate the protein of interest), cell lysis, removal of cell debris and 
aggregates through centrifugation and, finally, detection of the protein by WB 






Figure 6. Schematic illustration of CETSA approach. 
 
   The apparent aggregation temperature (Tagg or Tm) observed in the presence 
or in the absence of the drug can be compared; the occurrence of significant 
shifts in these parameters following cells treatment with the drug, demonstrate 
the actual stabilization of the target protein by the molecule. Therefore, a 
typical output form CESTA experiment is a comparison between apparent 
melting curves (or, more accurately, temperature-induced aggregation curves) 
16 
 
measured in treated and control cells; these curves report the amount of 
residual target protein detected at different temperatures and a potential 
thermal stabilization can be assessed and identified as a shift of the melting 
curve on the right side of the graphic (Fig. 7, in purple). 
Alternatively, an isothermal dose-response fingerprints CETSA (ITDRFCETSA) 
could be generated, in which the stabilization of the protein can be followed as 
a function of increasing ligand concentration. This latter experiment requires 
knowledge of the temperature at which the protein denatures and precipitates 
(Tagg or Tm).  
 
Figure 7. Principle of Cellular Thermal Shift Assay (CETSA) 
 
b) Drug Affinity Responsive Target Stability (DARTS) 
DARTS is a chemical proteomic techology performed to identify and study 
protein-ligand interactions.
29
 It is based on the idea that small molecule 
binding  its target protein may induce a protein stabilization, resulting in the 
resistance of a proteolytic enzyme (Fig. 8). This enhanced stability is 
postulated to result into a shift of the thermodynamic landscape of the protein 
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to favor the ligand-bound state, which prevents much of the protein‘s innate 
flexibility and movement from being realized. Therefore, DARTS can be 
applied to the initial identification of the target proteins of small molecules 
(Forward Chemical Genetics), but can also be used to validate potential 
protein-ligand interactions predicted or identified by other means and to 
estimate the affinity of interactions. This approach can be performed using 
intact cells, crude cell lysates and other complex protein mixtures (without 
requiring purified proteins), and in addition, it uses native and unmodified 
small molecules. 
 
 Figure 8. Principle of Drug Affinity Responsive Target Stability (DARTS). 
 
As shown in Figure 8, DARTS protocol starts from the incubation of cell 
lysates or of intact cells (which will be lysated after the incubation) with only 
vehicle (DMSO) and with the compound of interest. Subsequently, the 
samples undergo limited enzimatic digestion using a non specific protease 
(such as subtilisin), followed by electrophoresis 1D SDS-PAGE. Digested 
proteins will be then investigated by WB and/or MS. Finally, if the drug 
interacts with the protein of interest, the final output will be  higher levels of 
the protein in the treated sample than the control. There are different proteases 
that can be used for DARTS (e.g subtilisin, thermolysin and so on); in our 
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experiments subtilisin was selected, since we needed a rapid kinetic of 
hydrolysis and a protease with a broad specificity; thermolysin, another 
enzyme widely used for this technique, is not very stable and there is a 




c) Surface Plasmon Resonance (SPR) 
SPR is a non-invasive optical technique, based on the evanescent wave 
phenomenon, used to study the interactions of proteins with small molecules, 
protein conjugates, nucleic acids, lipid micelles and even larger particles such 
as viruses and whole cells.
30
 The binding between a compound in solution and 
its ligand immobilized on the surface of a sensor chip results in a change of the 
refractive index, that could be monitored in real time allowing the 
measurement of association and dissociation rates. Different concentrations of 
the compound in solution are used against the putative protein target, 
singularly immobilized on sensor chips .
31
  
A glass prism is coated with a thin layer of a noble metal (usually gold) to 
create a biosensor surface (Fig. 9A). The biomolecule (named ―ligand‖) is 
immobilized on the sensor surface. The metal layer possesses surface mobile 
electrons. At certain incidence angle the incoming beam of light disturbs these 
electrons causing changes in surface plasmon waves. Electrons ―resonate‖ 
giving a name to SPR phenomena, this particular incidence angle is called 
SPR angle. At the SPR angle, reflectivity drops to a minimum. However, the 
binding of the protein to a free compound in solution onto sensor‘s surface 
affects SPR conditions: refractive index increases and a shift of SPR angle 
occurs (Fig. 9B). The process is shown in real time by sensorgrams, where 
association (kon) and dissociation (koff) phases can be observed (Fig. 9C). The 





Figure 9.  Surface Plasmon Resonance (SPR)-based instrument. A) SPR- biosensor surface; 
B) shift of SPR angle; C)  SPR Sensorgram.  
 
d) Saturation Transfer Difference NMR (STD-NMR) 
The STD NMR experiment, at first described by Mayer & Meyer in 1999, is a 
spectroscopic technique used to study interactions, in solution, between a large 
molecule (protein) and a medium-small sized molecule (ligand).
32
 It is based 
on the Nuclear Overhauser Effect (NOE) and on the observation and analysis 
of the resonances of the ligand protons. 
The experiment is carried out by first registering a reference spectrum under 
conditions of thermal equilibrium with the irradiation frequency set at a value 
that is far from any ligand or protein signal (e.g. 40 ppm), i.e, the so-called 
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off-resonance spectrum (Fig. 10, top), which is used as reference with signal 
intensities I0.  
 
Figure 10. Scheme of the STD-NMR experiment showing the protein in surface 
representation and the non-exchangeable protons of the ligand as spheres. (Top) A 1D 
standard NMR experiments show only equilibrium intensities of the ligand in the free state 
(I0). (Middle) Upon selective saturation of some receptor signals, this is efficiently spread 
throughout the protein (yellow surface) by spin diffusion (intra-molecular NOEs). The fast 
exchange (transient binding) between the free and bound ligand states allows the transfer of 
magnetization (inter-molecular NOEs) from the receptor to the ligand protons in contact with 
the protein surface (salmon spheres, on-resonance spectrum). (Bottom) The difference 
spectrum (I0-Isat) only contains the ligand signals perturbed upon binding, whose intensities 
reflect the proximity of each proton to the protein surface. Adopted from Doctoral thesis of  
Garcia JCM, Alvarez JA, Nieto Mesa PM, insights on the structure and dynamics of 
glycosaminoglycans and their interactions with langerin: NMR and computational studies. 
2013.   
A second experiment is then recorded, in which the protein is selectively 
saturated (on-resonance spectrum; Fig. 10, middle), giving rise to ligand 
signals with Isatintensities. In general, the selective irradiation consists of a 
cascade of Gaussian or Adiabatic-shaped pulses (low power) that saturate only 
a region of the spectrum that contains a few protein resonances (but not ligand 
signals), e.g., the aliphatic (from 0 to -1 ppm) or aromatic region (around 7 
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ppm), for a specific period of time (saturation time; typically from 0.5 to 5-6 
seconds). The selective saturation is transferred to the whole protein via spin 





pathways (intra-molecular NOE; see Fig. 10, middle), being a quite efficient 
processes due to the typical large molecular weight of the receptor. Also, 
saturation is transferred from the protein to the bound ligand via spin diffusion 
through inter-molecular NOEs. The dissociation of the ligand will then 
transfer this saturation into the bulk solution where it accumulates during the 
saturation time of the experiment, as a result of the much slower relaxation in 
the unbound that the bound state. In particular, as in fast-exchanging protein-
ligand systems the enthalpic relaxation (R1) of fast-tumbling molecules 
(small) in the free state is much slower than the kinetic off-rate constant of 
binding (koff>> R1), the accumulation of ligands molecules containing some of 
their resonances perturbed (NOE of large molecule) results in the macroscopic 
detection of transferred saturation on the ligand signals in the saturated STD 
NMR spectrum (Isat; Fig.10, middle). Furthermore, for those hydrogen atoms 
of the ligand establishing close contacts to the protein surface (4-5 Å) these Isat 
values will be lower than the the I0 intensities, negative inter-molecular NOE, 
due to the transfer of the relaxation properties of the macromolecule to the 
small ligand in the bound state (Fig. 10, middle). By subtracting the off-
resonance from the on-resonance spectrum (I0-Isat) the difference or STD 
spectrum is obtained, which will just contain the proton signals of the ligand in 
close contact to the protein surface (Fig. 10, bottom), and where any signal 
coming from non-binding compounds is cancelled out. So, if a non-binder is 
present in solution, its resonances will not appear in the STD spectrum. 
Therefore, the difference spectrum, or the STD spectrum (ISTD = I0 - ISAT) 
yields only those resonances that experienced saturation in the on-resonance 







WaterLOGSY is a widely applied 1D ligand-observation technique for the 
detection of protein–ligand interactions. As the STD-NMR approach, 
WaterLOGSY is based on the NOESY experiment, and implies transfer of 
magnetization via a intermolecular NOE and spin diffusion. The originality of 
WaterLOGSY comes from the intervention of water molecules in the transfer 
pathway. 
33
 (Fig. 11a) 
 
Figure 11. a) WaterLOGSY principle; b) WaterLOGSY spectrum in comparison with Normal 
1D 
1
H-NMR spectrum. Adopted from FragmentTech.univ-lyon1.fr 
 
The bulk water magnetization is excited and transferred during the NOESY 
mixing time to the bound ligand via different mechanisms. The WaterLOGSY 
spectrum, which is recorded for the free ligand, contains the bound-state 
perturbed magnetization as long as the relaxation time T1 of the ligand is 
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greater than the dissociation rate constant koff. The inverted water 
magnetization can be transferred via different pathways to the bound ligand: 
a) direct transfer from water molecules immobilized in the protein 
binding site (water residence times greater than nanoseconds); 
b) chemical exchange between excited water and protein labile protons 
(amide, hydroxyl, amino, etc.) and propagation of the inverted magnetization 
to the ligand by intermolecular dipole–dipole crossrelaxation as well as spin 
diffusion via the protein– ligand complex; 
c) transfer from the water molecules found in the protein surface via the 
protein–ligand complex;  
In all the pathways, the ligands interact with water via water–ligand–protein or 
protein–ligand complexes, whose rotational correlation times yield negative 
cross-relaxation rates and exhibit a negative NOE with water (Fig. 11b 
waterlogsy spectrum). By contrast, small molecules that only interact with 
bulk water (non-binders) will experience much faster tumbling, which 
translates into a positive NOE (Fig. 11b Normal 1D spectrum). Therefore, 
opposite signs for signals from free versus protein-bound ligands are observed 




1.7  Outline of the thesis 
The PhD thesis is organized in three chapters: 
-  in Chapter 2, a screening by CETSA of a collection of ent-kaurane 
and ent-trachilobane diterpenes against Nucleolin is described. Once 
identified a diterpene ligand of Nucleolin, cell-free and cell-based 
assays were implemented to validate the interaction and to study the 
diterpene biological activity in cancer cells; 
-  in Chapter 3, ent-kaurane, ent-trachilobane, fusicoccane, labdane and 
clerodane diterpenes were screened by SPR against Heat Shock Protein 
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70 (Hsp70). Aiming to expand and validate our knowledge about the 
selected compound, multidisciplinary approaches were adopted, either 
to validate Hsp70/diterpene binding, carried out by MS, DARTS and 
molecular docking or to identify its biological activity, proved by WB, 
Flow Cytometry and ATPase assay; 
-  in Chapter 4, the target protein is the Heat Shock Protein 90 (Hsp90). 
A collection of fusicoccane and abietane diterpenes was double 
screened by SPR against Hsp90 and by MTT. The compounds 
emerging from the screening were investigated for their biological 
activity by Flow Citometry, WB, ATPase activity assays and  






















































































2.1 Nucleolin: structure and localizations  
Nucleolin (Fig. 1) is a protein encoded in humans by the NCL gene.  The 
human NCL gene is located on chromosome 2 and consists of 14 exons, 13 
introns and is long approximately 11kb. The intron 11 of the NCL gene 





Figure 1. Structure of RNA Binding Domain 1 (RBD1) of Nucleolin. Adopted from Allain 
FH et al. 2000; J Mol Biol. 303(2):227-41.   
 
 Firstly, Nucleolin was described by Orrick et al. (1973) and called C23 
because of its mobility on a two dimensional gel.
35
 The name Nucleolin is now 
widely used for this protein, which can represent as much as 10% of total 
nucleolar proteins.
36
 This protein is also often described as a 100-110 kDa 
protein; however, cloning of the cDNA of hamster Nucleolin revealed that it 
contained 713 amino acids, giving rise to a predicted molecular mass of 77 
kDa. This difference was attributed to the amino acid composition of the N-





Proteins homologous to human NCL were identified in rat, mouse, chicken 
and Xenopus laevis.
38
 Nucleolin is highly phosphorylated, methylated, and can 
also be ADP-ribosylated.
39,40
 Analysis of its amino acid sequence revealed the 
presence of three different structural domains (Fig. 2): 
1)  The N-terminal domain, showing highly acidic regions interspaced 
with basic sequences and containing multiple phosphorylation sites.  
2) The central domain, called RNA Binding Domain (RBD)  or RNA 
Recognition Motif (RRM), where four RNA binding domains are localized.  
3) The C-terminal domain, called GAR or RGG domain, rich in glycine, 




Several nucleolar proteins of different eukaryotic species exhibit a similar 
tripartite structural organization (Table 1).  
 
Figure 2. Schematic representation of the organization of three Nucleolin and ‗Nucleolin-like 
proteins‘. RBDs are defined from the 1 and 4 strand. (A) Organization of hamster 
Nucleolin: mouse, rat chicken, human and Xenopus laevis Nucleolin have the same 
organization. (B) Alfalfa and pea ‗Nucleolin-like protein‘ have the same organization. (C) 
Organization of gar2. Nsr1p possesses only 3 long acidic stretches. N-, N-terminal; C-, C-
terminal. 
Adopted from Ginisty H, Sicard H, Roger B, Bouvet P, structure and functions of Nucleolin. 





1) The N-terminal domain 
 
The length of this domain is highly variable among the different Nucleolin-
like proteins (Fig. 2). Highly acidic regions separated from each other by basic 
sequences represent a tipical feature of this domain. Acidic domains have been 
proposed to bind histone H1, and could be responsible for a displacement of 
H1 from its interaction with linker DNA, thus inducing chromatin 
decondensation. Indeed, the presence of the basic and repeated octapeptide 
motifs (XTPXKKXX, X being a non-polar residue) bears strong similarity to 
an analogous sequence of histone H1 and could be responsible for the ability 
of Nucleolin to modulate DNA condensation in chromatin.
42
 Besides, the N-
terminal domain of Nucleolin has been involved in many other protein-protein 
interactions, such as those with some ribosomal proteins.
43
 
The N-terminal domain of Nucleolin is highly phosphorylated,
38
 being this 






 and protein kinase C-δ.
46
 CK2 catalizes in vitro and in vivo phosphorylation 





phosphorylation occurs on threonine residues within the basic TPXKK repeat. 
Phosphorylation of Nucleolin by CK2 and p34
cdc2
 is highly regulated during 
the cell cycle. Extensive phosphorylation by CK2 occurs in interphase and by 
p34
cdc2
 in mitosis. This regulated phosphorylation of Nucleolin probably 




2) The RNA-binding domains 
 
Nucleolins from hamster, mouse, rat, human, chicken and Xenopus laevis 
possess four RNA-binding domains RBDs, also known as RRMs (Fig. 2 and 
Table 1). These domains, found in a large number of proteins implicated in 
various functions, are known to confer an RNA-binding specificity to the 
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protein they belong to.
47
 According to their RBDs sequence identity, 
Nucleolins and Nucleolin-like proteins can be divided in three groups. The 
first group includes Nucleolin from hamster, mouse, rat, human, chicken, 
Xenopus laevis and fish; in the second group there are yeast proteins such as 
gar2 and Nsr1p, and in the third group  plant proteins such as NucMs1 and 
Nucleolin from pea.
48
 RNAs associated with Nucleolin possess a small stem-
loop structure composed of a short stem (5 base pairs) and a 7-10 nt loop 
containing the motif U/G CCCGA, obtaining a minimal RNA-binding site 
named Nucleolin Recognition Element (NRE).
49
 The factors responsible for 
the binding affinity difference are not identified. Taken separately, none of the 
four individual RBDs interact significantly with RNA targets, but a peptide 
that contains the first two RBDs (RBD 1-2) is sufficient to account for 
Nucleolin/RNA binding specificity and affinity.
50
 Both domains participate in 
a joint interaction with the NRE using a different surface to contact the RNA. 
The determination of the structure of this RNA/protein complex has been 
investigated by NMR and X-ray high-resolution crystallography. The presence 
of several RBDs in Nucleolin structure suggests that Nucleolin could interact 
with multiple RNA targets.  
 








RBD 1 100 96 85 62 53 ND 
RBD 2 100 99 83 64 53 51 
RBD 3 100 93 96 70 67 64 
RBD 4 100 100 99 89 85 85 
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3) The C-terminal GAR/RGG domain 
 
The C-terminal domain is defined as Arg-Gly-Gly (RGG) repeats interspaced 
with other - often aromatic - amino acids; the motif RGG is particularly 
frequent in nucleolar proteins. The length of the GAR/RGG domain is variable 
among Nucleolins, with its sequence and arrangement of the repeats not well 
conserved. For example, plant Nucleolin-like proteins have a longer GAR 
domain than mammalian Nucleolins.
51
 The presence of this domain in a 
protein is associated with the presence of an RNA-binding domain (RBD or 
others). The presence of this GAR domain does not influence the binding 
affinity and specificity for the NRE sequence, but it could be involved in the 
interaction of Nucleolin RBD domains with targets located within large and 
complex RNA, such as rRNA.
49, 50
 The GAR domain protein-protein 
interactions are not well defined. It is not known how the GAR domain 
mediates protein-protein interactions, but since the GAR domain of Nucleolin 
interacts with only a subset of ribosomal proteins, these interactions seem to 
be specific. 
43
 After its discovery, it was found that Nucleolin contained high 
levels of NG,NG-dimethylarginines; this post-translational modification is 
found on arginines located in the GAR domain.
37,41
 This modification could be 
an important signal for the regulation of GAR/RNA interactions, the stability 
of the protein, or its localization. It is not known if this post-translational 





The intracellular localization of Nucleolin has been extensively studied by 





 and yeast cells.
53
 It is localized in the 
nucleolus, in the cytoplasm 
54
 and on the cell membrane 
55
(Fig. 3). This  
different localizations are linked to changes in Nucleolin isoelectric point 
and/or post-translational modifications, such as glycosylation, ADP-




 In fact, 
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Nucleolin translocation into the nucleus improves when it is dephosphorylated 
whereas pophorilated nucleolin is mainly moved into the cytoplasm.  
 Biochemical fractionation of the nucleoli has shown that the nucleolar 
fraction of Nucleolin represents more than 90% of the Nucleolin cellular pool, 
while the nucleoplasmic compartment does not represent more than 5% of the 
protein. 
56
 The cytoplasmic fraction of Nucleolin is difficult to estimate as it 
depends on the quality of the fractionation, or sensibility of the detection 
techniques that are used; however, it probably does not represent more than a 
few % of the total protein. In specific cytoplasmic structures, such as the 
centrosomes, centrosomal Nucleolin represents less than 0.1% of the total 
protein. 
57
 S. Nisole et al.  determined that the cell surface Nucleolin is less 
than 20% of the nuclear-free cytoplasmic fraction.
58
 In the different cell 
compartments, Nucleolin has different molecular targets that confer distinct 
functions (Fig. 3). 
 
Figure 3: localizations of Nucleolin (in red). 
Adopted from Kotb Abdelmohsen & Myriam Gorospe  RNA-binding protein nucleolin in 
disease. 2012; RNA Biology. 9:799-808.  
 
The predominant localization in the nucleolus represent an important aspect of 
Nucleolin profiling of its functions.
59, 60
 Nucleolin is mainly observed in the 
Dense Fibrillar Compartment (DFC), whreas it is less abundant in the 
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Granular Compartment (GC), and almost absent in the Fibrillar Center (FC).
61
 
How Nucleolin accumulates in the nucleolus remains an important question: 
several studies were performed to identify the Nucleolin domains responsible 
for the nucleolar localization
62
 but, the obtained results showed  that Nucleolin 
does not contain a single, linear nucleolar targeting signal. The well-defined 
bipartite nuclear localization signal (NLS) of Nucleolin 
(KRKKEMANKSAPEAKKKK) is used to enter in the nucleus and then the 
protein probably accumulates within the nucleolus as a consequence of its 
binding to other nucleolar components (probably rRNA) via the RNA binding 
domains and the C-terminal RGG domain. The RNA-binding domains of 
nucleolin are crucial for its nucleolar localization, but are unable by 
themselves to target hybrid proteins to the nucleolus. The C-terminal GAR 




Nucleolin has also been observed in the plasma membrane of several cell 
lines, using immunofluorescence and electron microscopy. This localization is 
surprising, because Nucleolin neither possesses a transmembrane hydrophobic 
domain nor a plasma membrane targeting sequence.
64
  Ding et at. 
demonstrated that Nucleolin traslocation to the cell membrane is mediated by 
Heat Shock Protein 70 (Hsp70). This chaperon interacts with Nucleolin in 
endothelial cells via its peptide-binding domain and the RNA-binding domain 
3 and 4 of Nucleolin. Phosphorylation of Nucleolin by either protein kinase C-
ξ or casein kinase 2 mediates Nucleolin interaction with Hsp70 and the surface 
expression. Moreover, Hsp70 regulates Nucleolin translocation via stabilizing 
it and enhancing its interaction with nonmuscle myosin heavy chain 9. On the 
plasma membrane, Nucleolin interacts with several proteins involved in cell 






2.1.1 Roles of Nucleolin in physiological and pathological pathways 
The multiple sub-cellular localizations of Nucleolin are directly connected to 
its physiological and pathological functions (Fig. 4): 
- in the nucleolus, it is directly involved in ribosome biogenesis,66 
chromatin remodeling,
67
 transcriptional regulation 
68
 and telomerase activity;
69
  
- in the nucleoplasm, Nucleolin interacts with several RNAs and proteins 




- in the cytoplasm; Nucleolin constantly shuttles between nucleus and 
cytoplasm where it is involved in many non nucleolar functions, e.g. 
import/export of ribosomal proteins,  centrosome duplication 
59
 as well as 
post-transcriptional and translational regulation of various mRNAs 
71
 
including p53  
72





- on the cell surface Nucleolin behaves as receptor, binding to several 
proteins, thus inducing tumorigenesis (cell migration, adesion, angiogenesis), 











Figure 4. The cellular compartment locations of Nucleolin (red dots). (a) In the nucleolus, 
association of Nucleolin with nucleolar chromatin (rDNA) could be involved in the regulation 
of Pol I transcription. (b) Nucleolin has been seen on nascent pre-rRNA transcripts and is 
believed to participate in co-transcriptional pre-rRNA folding, (c) maturation at the first 
processing site and (d) assembly of pre-rRNA with ribosomal proteins. (e) The shuttling of 
Nucleolin between the nucleus and the cytoplasm might participate in the import and/or export 
of several nucleolar components or proteins, such as ribosomal proteins. (f) In the 
nucleoplasm, Nucleolin has been also found associated with several genes transcribed by Pol 
II and with mRNAs, with functions from (g) the regulation of translation to (h) mRNA 
stability. (i) A large number of reports have identified nucleolin on the cell membrane, with 
potential roles in cell migration and adhesion and virus infection. 
Adopted from Fabien Mongelard and Philippe Bouvet. Nucleolin: a multiFACeTed protein. 
TRENDS in Cell Biology. 2007; 17: 80-86.  
2.1.2 Roles of Nucleolin in ribosome biogenesis  
In the nucleolus, Nucleolin plays many functions, specially in ribosome 
biogenesis (Fig. 4):  
- it is a chromatin co-remodeler, as it facilitates the interaction between 
nucleosomes and the remodeling complex of chromatin;  
67
  
- it is a histone chaperone, with functional similarity to the ―facilitates 
chromatin transcription‖ complex (FACT); 
67
  
- it is involved in the regulation of RNA polymerase I trascription and 





- it is invoved in the proper folding and maturation of the preribosomal 
RNA (pre-rRNA); 
- it participates in the ribosome assembly; 77  
According to its histone chaperone activity, Nucleolin promotes RNA 
transcription through nucleosomes. Histone chaperones are key factors for the 
dynamic organization of chromatin template. They mediate: 
- histone storage; 
- translocation of histones to the nucleus;  
- exchange and deposition of histones onto the DNA during replication-
dependent chromatin assembly;  
- chromatin reorganization not only during elongation, but also during 
initiation of RNA transcription; 
 Chromatin assembly is a two-step process: deposition of a H3–H4 tetramer on 
DNA followed by the deposition of two H2A–H2B dimers. Various histone 
chaperones and ATPdependent chromatin remodeling factors facilitate the 
organization of nucleosomes into a regularly spaced array. Nucleolin directly 
binds to H2A–H2B dimers 
76
 and facilitates the assembly of nucleosomes on 
naked DNA, presumably by incorporating H2A–H2B dimers into auto-
assembled tetrasomes ((H3–H4)2 tetramer acceptor). This effect of Nucleolin 
on the dynamics of H2A–H2B dimers facilitates the passage of the RNA 
polymerase II through nucleosomes. The ability of Nucleolin in increasing 
H2A–H2B turnover is a key factor to understand its co-remodeling activity. 
The spontaneous or Nucleolin-induced disassembly of one H2A–H2B unit 
would be expected to lead to a destabilization of the histone octamer particles.  




Figure 5. The histone chaperone and FACT-like activities of Nucleolin. In vitro, Nucleolin 
can, similar to FACT, destabilize nucleosomes to promote the formation of hexasomes (loss of 
one H2A–H2B dimer). This helps the passage of polymerase II through chromatin templates. 
The histone chaperone activity of Nucleolin helps the reformation of nucleosomal structures 
after the passage of the polymerase. 
Adopted from Fabien Mongelard and Philippe Bouvet. Nucleolin: a multiFACeTed protein. 
TRENDS in Cell Biology. 2007; 17: 80-86. 
 
The ―facilitates chromatin transcription‖ (FACT) complex is required to 
overcome the nucleosomal barrier and to promote a modest but significant 
level of transcription elongation. Therefore, FACT is also itself a histone 
chaperone and facilitates the loss of an H2A–H2B dimer upon polymerase II 
transcription, enabling the passage of the polymerase through the nucleosomal 
particle.
78
   
Nucleolin is also involved in the regulation of rRNA transcription. Indeed, 
following inhibition of rRNA transcription, a rapid release of Nucleolin from 
the dense fibrillar zone of the nucleolus is observed,
79
 demonstrating that its 
presence in this subnucleolar compartment is  dependant upon rRNA 
transcription. A model related to Nucleolin ability to interact with rRNA has 
been proposed by Bouche et al., where Nucleolin is involved in the regulation 
of rRNA transcription elongation through the binding of its RNA-binding 
domains with the nascent rRNA transcript. The N-terminal domain, instead, 
interacts with the polymerase I machinery, which would block transcription 
elongation. In this model, the phosphorylation of Nucleolin by CK2 during 
interphase would be required to proteolyse Nucleolin (between the N- and 
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central domains) and to release the transcription complex, while the central 
and C-terminal domains of Nucleolin could remain bound to the rRNA and 
participate in the pre-ribosome assembly.
80
 
The ability of Nucleolin in vitro to promote the formation of secondary 
structures in complex RNAs, 
81
 and its association with preribosomal particles 
in vivo,
82
 suggest that Nucleolin could be required for the correct assembly of 
these particles. Therefore, Nucleolin can play a role as an assembly factor, 
bringing together a correctly folded rRNA and the other components necessary 
for rRNA maturation and/or assembly of the ribosome. The GAR domain of 
Nucleolin is implicated in some of these interactions. 
43
 The interaction of 
Nucleolin with these ribosomal proteins further supports its role at an early 
step of ribosome assembly. 
2.1.3  Nucleolin as shuttle between nucleus and cytoplasm  
Despite Nucleolin is found almost exclusively into the nucleolus, assays based 
on interspecies heterokaryons have shown that Nucleolin shuttles between 
nucleus and cytoplasm. However, a very small amount of Nucleolin is able to 
migrate to the cytoplasm. In the heterokaryon system, the N-terminal domain 
of Nucleolin is required for efficient shuttling, but it is unable to increase the 
nuclear export of an heterologous protein, indicating that Nucleolin does not 
contain a positively acting export signal.
83
 In addition, its cytoplasmic 
localization is related to its phosphorylation by p34
cdc2
, whereas the nuclear 
translocation is correlated with a dephosphorylation of Nucleolin. These data 
show that phosphorylation of its N-terminal domain can regulate the function 
of Nucleolin NLS.
63
 Regarding to the C-terminal domain, it was shown that 
the GAR domain of Nucleolin reduced slightly the export process.
83
 The 
discovery that this protein is able to shuttle, even under specific conditions, 
has raised the possibility that it can be involved in the nuclear import of 
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ribosomal components (like ribosomal proteins), or in the nuclear export of the 
ribosomal particles.  
2.1.4  Nucleolin as receptor on the cell surface  
Nucleolin has been observed at the plasma membrane of several cell lines 
using immunofluorescence and electron microscopy.
84
 The expression of 
Nucleolin at the plasma membrane is increased in  several tumor cells 
85
 and in 
endothelial cells during angiogenesis.
86
 There are several evidences indicating 
that Nucleolin located in plasma membrane can facilitate the binding of HIV 
on host cell surface, and its entrance. Moreover, Nucleolin has been shown to 
promote inflammation, enhancing the internalization of lipopolysaccharides 
from the cell membrane to the cytosol.
75
 Therefore, Nucleolin is believed to be 
a useful signature for cancer, inflammation and viral infection diagnostics and 
can be an interesting target for the development of new drugs. 
2.1.5  Nucleolin as tumor marker: therapeutic strategies 
An altered expression and function of Nucleolin has been observed in several 
cancers. For instance: 
- an increase of Nucleolin expression is observed in tumor tissue from 
colorectal cancer human patients;
87
  
- it is also over-expressed in tumor tissues from gastric cancer, and a 




- in human breast cancer tumors, Nucleolin is over-expressed (from 3 to 




- higher Nucleolin mRNA or protein levels are also observed in 





- Nucleolin expression is also increased in lung cancer tissues from 
human patients and associated with largest tumors;
91
  
- in glioblastoma cells, the presence of glycosylated Nucleolin at the cell 
surface increases with the malignancy of the human tumor;
85
 
- in human melanoma cells, a specific glycosylated form of Nucleolin is 
observed and the inhibition of cell surface Nucleolin in a mouse model, delays 




- in cervical cancer, Nucleolin expression is directly linked to human 




A major challenge is to understand the contribution of Nucleolin to the 
development of these cancers. In some cases, Nucleolin deregulation may just 
be the consequences of the pathological state, whereas in other situations the 
deregulation of Nucleolin may contribute to the initiation or the progression of 
the disease. 
As shown in figure 6, Nucleolin can play several functions in cancer 
progression: 
-  in the nucleoplasm, Nucleolin binds promoters of genes that are over-
expressed in cancer (such as c-myc) and promotes their transcription;  
- in the cytoplasm, Nucleolin affects mRNA turnover by interacting with 
the 3′-untranslated region of several target mRNAs of proteins important for 
cancer development (p53, Bcl2 or AKT1 mRNAs). Particularly, binding to 
Bcl2 mRNA,
73
 Nucleolin prevents its proteolysis inferred by exosoms, 
increasing Bcl2 levels and improving anti-apoptosis. In addition, interacting 
with AKT1 mRNA,
74
 Nucleolin enhances its translation increasing cell 
proliferation. Nucleolin also interacts with miRNAs to affect the expression of 
oncogenes and tumor suppressor genes;  
41 
 
- at the plasma membrane, Nucleolin interacts with several proteins 
involved in cell proliferation, apoptosis and angiogenesis; 
- Nucleolin interacts with Fas, member of the tumor necrosis factor 
superfamily of apoptosis receptors,  inhibiting apoptosis;
94
  
- Nucleolin interaction with ErbB195 and Ras96 at the plasma membrane 
favors cell proliferation;  
- it can bind to the growth factors Pleiotrophin (PTN) 97 (inducing cell 
migration) and midkine 
98
 (promoting cell survival);  
- numerous other key proteins involved in tumorigenesis and 
angiogenesis have been shown to interact with Nucleolin and act through cell 
surface Nucleolin as for instance Hepatocyte Growth Factor (HGF),
99
 
Vascular Endothelial Growth Factor (VEGF)
100
 and tumor necrosis factor 









Figure 6. Nucleolin (represented by the red star) mediates cancer development in all cell 
compartments. In the nucleus and nucleolus, Nucleolin modulates the quantity of synthesized 
ribosomes. Firstly, RNA Polymerase I transcription and ribosomes synthesis are increased by 
Nucleolin (1). By binding unmethylated rDNA, it allows the mantenance of a euchromatine 
active state (5). Nucleolin helps the rRNA maturation and the cleavage of preRNA (2). It is 
required for RNA polymerase II transcription (3) and ribosomal proteins synthesis (4). These 
ribosomal proteins can be imported by Nucleolin from the cytoplasm to the nucleus and to the 
nucleolus (4). Nucleoplasmatic Nucleolin binds also several promoters of genes that are 
overexpressed in cancer, like c-myc and promotes their transcription (6). Cytosolic Nucleolin 
is important for centrosome function (7) and binds to several mRNAs to promote their 
translation (8) like for example mRNAs coding for proteins important for cancer progression 
(p53, Bcl2 or AKT mRNAs). Nucleolin also interacts with miRNAs to affect the expression of 
oncogenes and tumor suppressor genes (9). On cell surface, Nucleolin interacts with the 
apoptosis pathway protein Fas, blocking cell death (10). Nucleolin can also bind to Ras GDP 
and RasGTP, increasing proliferation, migration, resistance to apoptosis through the Map 
Kinase/AKT pathways. Nucleolin/RasGTP interaction increases NCL/ErbB1 binding (11). 
Cell surface Nucleolin can also participate to the translocation of several entities such as virus 
and angiogenic factors from the cell surface to the nuclear compartment (12). 
Adopted from: C. M. Berger, X. Gaume, P. Bouvet,The roles of Nucleolin subcellular 







2.1.6 Nucleolin Inhibitors 
Some compounds able to block Nucleolin activity have been reported. 
Unfortunely, this protein is involved in so many pathways that achieving its 
selective inhibiton is quite hard.  
One interesting Nucleolin-inhibitory molecule is the aptamer AS1411 (figure 
7).
102
 This 26-base guanine-rich oligodeoxynucleotide quadruplex-forming 
aptamer is promising for therapy as it can target various Nucleolin pathways: 
- AS1411 induces relocalization of the protein arginine 
methyltransferase 5-Nucleolin complex from the nucleolus to the 
cytoplasm,
73,103
 probably altering ribosome synthesis;  
- AS1411 is internalized via binding to cell surface Nucleolin; inside the 
cell it may prevent Nucleolin from binding to and stabilizing mRNA of the 
anti-apoptotic Bcl2, thereby destabilizing Bcl2 mRNA and leading to a 
reduction in Bcl2 protein synthesis. This may lead to the induction of 
apoptosis;
102
   
- this aptamer also modulates the interaction between Nucleolin and the 
microprocessor complex involved in miRNA synthesis. Thus, AS1411 can 
reduce the level of Nucleolin-dependant miRNAs, such as miR-21, miR-221, 




Phase I and II human clinical trials to treat acute myeloid leukemia have 







         
 
Figure 7. Structure and mechanism of action of AS1411. AS1411 self-anneals into a dimer 
and adapts a three-dimensional structure conferred by eight guanosine-quarters (gray circles). 
The  black squares are the thymidine bases. AS1411 is internalized into the cell by binding 
cell surface Nucleolin. Into the cytoplasm it prevents Nucleolin from binding and stabilizing 
the mRNA of the anti-apoptotic Bcl2, thereby destabilizing its mRNA and leading to a 
reduction of Bcl2 protein synthesis. Into the nucleus, AS1411 inhibits DNA replication and 
induces S-phase cell cycle arrest.   
Adopted from R. C. Ireson and L. R. Kelland, Discovery and development of anticancer 
aptamers. 2006; Molecular Cancer Therapeutics. 5: 2957-2962. 
 
A small molecule quarfloxin (also known as CX-3543, figure 8), which 
selectively disrupt Nucleolin-rDNA interaction thereby inhibiting RNA 
polymerase I transcription, was found to induce apoptosis in cancer cells. 







Figure 8. Structure of quarfloxin. 
 
The cell surface Nucleolin is probably the most promising target for cancer 
therapy. Indeed, Nucleolin is over expressed on the membrane of cancer cells, 
compared to normal cells. Thus, chemotherapy may be less toxic since a drug 
would easily target the cell surface Nucleolin of tumor cells without altering it 
in the nucleus. For example, the HB-19 pseudo-peptide binds surface Nuclelin 
without interacting with nuclear Nucleolin.
106
 Recent studies show how HB-19 
can inhibit its oncogenic action in vitro and in vivo, by binding to the C-
terminal domain of cell surface Nucleolin. Although additional evaluations of 
these Nucleolin aptamers are required, these preliminary studies suggest that 
such molecules could be relevant for both cancer therapy and diagnostic. 
Another inhibitor of Nucleolin, identified by our research group, is the ent-
kaurane diterpene Oridonin.
19
 Oridonin is the first identified plant small 
molecule inhibiting Nucleolin. After demostrating its interaction with 
Nucleolin in cancer cells (Jurkat and HeLa) by cell-free and cell based assays 
(SPR, CETSA, DARTS), its cytotoxic effect in Jurkat cells ater 24h and a cell 
cycle arrest in G2/M phase were proved. In addition, Oridonin shows 
inhibition of protein synthesis and reduction of the levels of the proteins AKT 
and Bcl2 and of the respective mRNAs. There is also another interesting result 
emerging from our studies: Oridonin can inhibit simultaneously two proteins 
crucial for cancer development and progression: Hsp70 and Nucleolin. This 
46 
 
finding could actually explain the efficiency of Oridonin as antitumor agent 
and its ability in interfere with many different pathways.
19
 The two proteins 
are functionally related, as Hsp70 has been shown to prevent degradation and 
cleavage of Nucleolin in cancer cells following exogenous stresses,
107,108
 and 
to regulate Nucleolin translocation to cell surface.
106
 Taken together, our 
results suggested Oridonin as an interesting starting point to obtain small-
molecules able to modulate Nucleolin activity. Furthermore, the present 
discovery of the first plant small-molecule interactor of Nucleolin provides a 
proof-of-principle evidence of modulation of Nucleolin activity induced by a 
small-molecule. 
2.1.7 Aim of the project 
In this frame, our aim was to to set-up, optimize, develop, and apply cell-free 
and cell-based techniques to identify new bioactive diterpene as Nucleolin 
inhibitors  and to elucidate their molecular mechanism of action. Our project 
started from a screening of several plant diterpenes against Nucleolin in order to 
find a potential binder; to achieve this goal, a Cellular Thermal Shift Assay 
(CETSA) was performed. This screening led us to obtain the diterpene 6,19-
dihydroxy-ent-trachiloban-17-oic acid (12) as a promising ligand of Nucleolin. To 
validate the interaction and to investigate more in detail the mechanism of action 
of 12, several cell-free, cell-based and chemical proteomic approaches were 
carried out: WB, MTT, Flow Citometry, RTq-PCR,  LC-MS/MS, DARTS,  SPR,  












Results and discussion 
 
2.2 Screening of diterpenes by Cellular Thermal Shift Assay (CETSA) 
Our study started from a Reverse Chemical Genetics (RCG) approach, 
selecting Nucleolin as target. The choice of this target derived from previous 
studies performed by our research group, where Nucleolin was identified, by a  
Forward Chemical Genetics (FCG) strategy, as target of Oridonin, a bioactive 
diterpene isolated from Isodon rubescens (Lamiaceae) with interesting 




In order to find further diterpenes able to inhibit Nucleolin, a small library 
based on structural similarity with Oridonin scaffold, was screened by 
performing Cellular Thermal Shift Assay (CETSA) in Jurkat cells (leukemia T 
cells). CETSA allows to carry out a qualitative and quantitative analyses of the 
direct interaction of a drug candidate to a target protein inside a cell.
28
 In 
particular, this approach offers the opportunity to firmly link the observed 
phenotypic response to a compound with a particular target engagement.       
CETSA, set up by Molina and coworkers in 2013, relies on the principle of 
thermodynamic stabilization inferred to the protein as a result of ligand 
binding, which can be used for the estimation of binding free energies as well 
other thermodynamic properties for isolated systems at equilibrium. Basically, 
the shift in thermal stability is estimated by measuring the amount of 
remaining soluble target protein in treated and control experiments at different 
temperatures. CESTA protocol starts with the treatment of cells with the 
molecule of interest and vehicle (DMSO) as control, followed by cell heating 
(to denaturate and precipitate the protein of interest), cell lysis, removal of cell 
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debris and aggregates through centrifugation and, finally, detection of the 











Figure 9: Schematic illustration of CETSA approach. 
 
   The apparent aggregation temperature (Tagg or Tm) observed in the presence 
or in the absence of the drug can be evaluated; the occurence of significant 
shifts in these parameters following cells treatment with the drug, demonstrate 
the actual stabilization of the target protein by the drug. Therefore, a typical 
output form CESTA experiment is a comparison between apparent melting 
curves (or, more accurately, temperature-induced aggregation curves) 
measured in treated and control cells; these curves report the amount of 
residual target protein detected at different temperatures and a potential 
thermal stabilization can be assessed and identified as a shift of the melting 
curve on the right side of the graphic (Fig. 10, in purple). 
Alternatively, an isothermal dose-response fingerprints CETSA (ITDRFCETSA) 
is generated, in which the stabilization of the protein can be evaluated as a 
function of increasing ligand concentration. This latter experiment requires 
knowledge of the temperature at which the protein denatures and precipitates 




Figure 10: Cellular Thermal Shift Assay (CETSA) 
 
Nucleolin was confirmed as oridonin target by CETSA experiments in Jurkat 
cells,
19
 and the stabilization of Nucleolin was inferred by oridonin at 55°C, 
Tagg of Nucleolin. On these bases, we performed a screening of several 
diterpenes as Nucleolin binders at this Tagg in Jurkat cells. We screened 16 
diterpenes, with ent-kaurane and some ent-trachilobane skeletons (Fig. 11); 
Most of these diterpenes were isolated from aerial parts of Psiadia punctulata 
(DC) Vatke (Asteraceae), and oridonin was used as positive control. The 
choice of these diterpenes was due to their similarity in terms of chemical 
scaffold in comparison with oridonin. 
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Figure 11. Structures of diterpenes screened against Nucleolin by CETSA.   
 
As shown in figure 12, WB results indicated that the main ligands for 
Nucleolin stabilization at 55 °C were compounds 1, 5, 6, 7, 12, 13 and 15. 
Compound 1 shares with oridonin the presence of an α,β-unsaturated carbonyl 
group and an the methylene group in R. They seem to be important for the 
interaction with Nucleolin. For the other compounds was not possible to 
predict structure-activity relations.   
 
Figura 12: Screening of diterpenes in Jurkat cells monitored by WB using CETSA. 
 
Our attention was focused on 12,  the 6,19-dihydroxy-ent-trachiloban-17-oic 
acid, a diterpene with trachilobanic scaffold isolated from Psiadia punctulata 
(Vatke) Asteraceae, which was found as the compound that showed the higher 
stabilization of Nucleolin at its Tagg  (Fig. 13).     
 
 
Figura 13: Structure of  6,19-dihydroxy-ent-trachiloban-17-oic acid (12) 
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2.2.1 Biological activity of 6,19-dihydroxy-ent-trachiloban-17-oic acid in 
Jurkat and HeLa cells 
The biological activity of N-12 was investigated by MTT assay in liquid and 
solid cancer cells, respectively Jurkat (leukemia T cells) and HeLa cells 
(cervical carcinoma cells), and also on nontumor human peripheral blood 
mononuclear cell line (PBMC). After treatment of the cells with 12 (10µM, 
30µM and 70µM  for 48h),  higher cytotoxicity in HeLa cells (IC50= 25 ± 0.5 
µM) than Jurkat cells (IC50= 50 ± 1.2 µM) was observed (table 2). Therefore, 
HeLa cells were selected for our  cell-based studies. On PBMC cells 12 did 
not show cytotoxic activity (IC50 up to 100µM).  
Table 2. IC50 (μM) in HeLa and Jurkat  cells by MTT assay. HeLa and Jurkat cells were 
treated with DMSO (ctrl) or 12 (10µM, 30µM e 70µM)  for 48h.  
Compound Jurkat HeLa PMBC 
12 50 ± 1.2 µM 25 ± 0.5 µM >100 µM 
Data represent the mean ± SD of  3 different exeriment. 
 
Moreover, to study more in detail the biological activity of 12 on HeLa cells, a 
cytofluorimetric analysis was performed. Particularly, HeLa cells were 
incubated with 12 (20 µM and 40 µM) for 48h. Compound 12 was found to 
arrest HeLa cell cycle at subG0/G1 phase (Fig. 14). 
       
Figure 14. Effect of 12 on cell cycle progression. Flow cytometric evaluation of DNA content 
in HeLa cells treated with DMSO (control) or 12 (20µM and 40µM) for 48h. On the Y axis: 
the percentages of cells in subG0G1 (hypodiploidia) and in each cell cycle phase of 12-treated 
cells subtracted for the corresponding percentages of control cells. Results are expressed as 
means ± SD of three experiments performed in duplicate (**p<0.005, *p<0.05).  
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In order to understand if the subG0/G1 cell cycle arrest was due to apoptosis or 
necrosis events,  Annexin V, FITC Coniugate/PI protocol was implemented. 
109
The results, analyzed by flow cytometry, showed HeLa cells in late (9.67%) 
and early (8.01%)  apoptosis after treatment with 12 10 µM for 48h and in late 
(11.3%) and early (28.5%) apoptosis with 12 20µM for 48h (Fig. 15a, b and 
c). No significative necrosis effects were observed. Apoptosis results were 
also confirmed by cleavage of PARP, increased after treatment of HeLa with 
12 10 µM and 20µM for 48h (Fig. 15d).   
 
Figure 15. Flow cytometry experiment using Annexin V-FITC/PI protocol. a) HeLa cells 
treated with DMSO (control) for 48h. b) HeLa cells treated with 12 20 µM for 48h. c) HeLa 
cells treated with PEITC (positive control) 10 µM for 24h. d) WB of HeLa treated with 12 10 
µM and 20 µM for 24h and 48h. GAPDH was used as loading control. The blots are 




2.2.2 Nucleolin-12 interaction achieved by CETSA in HeLa cells 
The next step of our study was to demonstrate Nucleolin-12 interaction by 
CETSA also in HeLa cells. Firstly, we had to identify the Tagg of Nucleolin 
also for this cell line: HeLa cells were incubated with 12 (20 µM),  DMSO 
(control), and oridonin (5 µM)  as positive control for 2h at 37 °C. Afterwards, 
the samples were divided in 8 aliquots, and each of those was subjected to a 5 
minute incubation at a specific temperature, in the range from 38.4 °C up to 
61.3 °C. Samples where then lysated and centrifuged, in attempt to separate 
the soluble proteins from the aggregated and precipitated ones, and Nucleolin 
levels were evaluated by WB analysis. In Fig. 16 we can  observe a gradual 
decrease of the soluble portion of the protein in the control and an increase of 
its levels in the treated samples, due to the thermal stabilization inferred by 
oridonin and 12 in the range of temperatures 52.8-55.6 °C. In our experiments, 
55.5 ºC was the appropriate temperature to appreciate thermal stabilization of 
Nucleolin, as the amount of soluble protein at this temperature in 12 and 
oridonin-treated cells was about 2 or 3 times higher than that observed in the 




Figure 16. Tagg  of Nucleolin monitored by CETSA. WB on Nucleolin levels after treatment of  
HeLa cells with DMSO (control), oridonin 5 µM (positive control) and 12 20µM. Therefore, 
treated and untreated HeLa cells were heated and then the soluble amount of Nucleolin by WB 
was evaluated. 
 
 In Figure 17, densitometry-based quantification of western blot signals (ratio 
Nucleolin/GAPDH depending on the temperature) was graphed and melting 
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curves of Nucleolin for control (DMSO), positive control (Oridonin)  and 
treated samples with 12  were reported.   
 
Figure 17. Apparent melting curves of Nucleolin in HeLa cells. Densitometry-based 
quantification of WB signals was graphed (Nucleolin intensities normalized to GAPDH 
intensities for each data point). Results are expressed as means ± SD of three experiment 
performed in duplicate. 
 
Comparing the treated curves with the control, a shift of the curves of treated 
with 12 and oridonin on the right side of the graphic can be observed, 
indicating that the Tagg of Nucleolin is higher due to its interaction with the 
compounds which protect Nucleolin from the denaturation under heating 
conditions.   
In order to investigate the kinetic profile of the engagement of Nucleolin in the 
cell, HeLa cells were treated with DMSO (control), 15-ketoatractyligenin 
methyl ester (SR2017), used as negative control since from previous studies in 
our research group it was identified as a non-binder of Nucleolin 
19
 (Fig. 18) 
and 12 (5µM and 20µM) for 1h up to 4h. 
 
             Figure 18. Structure of 15- ketoatractyligenin methyl ester (SR2017) 
56 
 
The time-course experiment revealed that the maximum binding was observed 
after 2h of incubation with  12  (5µM) (Fig. 19, highlighted in blue); after that, 
the difference between treated and control samples decreased, and it became 
negligible after 4 h of incubation.  
 
Figure 19: Kinetic profile of the engagement of Nucleolin by 12 in cells using CETSA. HeLa 
cells were treated with 12 (5 µM and 20 µM) for 1h up to 4h. Each samples was heated and 
then the soluble amount of Nucleolin was evaluated by WB analysis. 15-chetoatractiligenin 
methil ester (SR2017) was used as negative control.  
 
Taking advantage of the defined Tagg of Nucleolin, we carried out an 
ITDFCETSA experiment to establish the half-maximal effective dose (EC50) of  
Nucleolin/12 complex. Therefore, HeLa cells were treated with a wide range 
of concentrations of 12, from 0.1 to 20 µM (Figure 20a), while incubation time 
(2h) and temperature (Tagg = 55.3 °C) were kept constant. Increased 
stabilization of Nucleolin in a dose-dependent manner was observed, and the 
obtained EC50 was 5 µM (Figure 20b).              
 
Figura 20. a) CETSA in HeLa cells in presence of  DMSO or  12 (from 0,1 to 20  M) at 55.3  




2.2.3 Study of Nucleolin/12 interaction by DARTS in HeLa cells 
Nucleolin/12 interaction was studied by Drug Affinity Responsive Target 
Stability (DARTS) 
29
 in HeLa cells. Firstly, a preliminar optimization of the 
DARTS protocol had to be set up to select the best limited proteolysis 
condition with subtilisin. Thus, lysates from human HeLa cells were split into 
different aliquots which  underwent digestion with different concentrations of 
subtilisin for 30 min and 60 min at 25°C and 37°C. The digestion was stopped 
by adding sample loading buffer and boiling immediately. Each sample was 
then loaded onto 10% SDS/PAGE gels, stained with Fixing solution for 30min 
and Brilliant Blue G-Colloidal over-night, and finally washed with water. 
Achieved results showed that ratio of 1:6000 enzyme:lysate (w:w) at 25°C for 
30 min resulted as the best experimental condition (figure 21b).              
 
Figure 21: Optimization of DARTS protocol. a) Scheme of different conditions used for 
DARTS optimization;  b) HeLa lysates with and without subtilisin (1:6000 w:w). 
  
Hence, HeLa cells were treated with 12 (20 µM) for 2h; after the incubation, 
the cells underwent lysis with RIPA buffer, and the resulting protein extract 
was subjected to enzimatic digestion, carried out by adding  subtilisin (1:6000 
w/w) for 30 minutes at 25 °C. Subsequently, the partially digested proteins 
were fractionated by SDS-PAGE; each sample was divided in two aliquots, 
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each loaded on a gel: in the first gel, the proteins were transferred into 
nitrocellulose membranes to perform a WB analysis.  As shown in Figure 22b, 
in the sample treated with subtilisin and 12 there was an enrichment of 
Nucleolin in comparison with the sample treated with only subtilisin, meaning 
that the diterpene interacted with Nucleolin protecting it from the enzymatic 
proteolysis. 
                          
                             
Figura 22: a) 1D SDS PAGE after digestion with subtilisin 1:6000 w:w  using 12 20µM  b) 
WB analysis of DARTS results. GAPDH was included as a loading control. The blots are 
representative of at least two different experiments with similar results. 
 
The second gel was treated with Fixing Solution for 30 min, stained with 
Comassie Blue Colloidal, and each lane of control and treated samples was cut 
into five pieces, digested with tripsin and analyzed by LC-MS/MS.                             
In order to evaluate the relative abundance of Nucleolin in treated and control 
samples, we carried out further data analyses by Mass Spectrometry. Bands of 
each lane underwent a digestion protocol with tripsin and then analyzed by 
LC-MS/MS. Subsequently, each raw file was analyzed using Max Quant 
software, using a label-free quantification (LFQ) ―within groups‖  method 
(each band of the same lane was united). In Table 3, Nucleolin intensities in 




Achieved results were in agreement with DARTS data obtained by WB, since 
the LFQ total intensity of treated samples is higher than the LFQ total intensity 
of control samples. 
Table 3. Max Quant software data. Control (DMSO) and treated (12 20 µM) samples.  
 
Data are representative of at least two different experiments with similar results. 
According to our previous Isotermal Dose Response Fingerprint CETSA 
(ITDRFCETSA) results, where the EC50 for Nucleolin/12 was 5 µM, we carried 
out further DARTS experiments using this concentration. Therefore, different 
proteolitic profiles among the lane of control (only DMSO), the lane of treated 
with subtilisin and the lane treated with subtilisin and 12 were observed (Fig 
23a).  
              
Figura 23: a) 1D SDS PAGE after digestion with subtilisin 1:6000 w:w  using 5µM 12; b) 
WB analysis of DARTS results. GAPDH was included as a loading control. The blots are 
representative of at least two different experiments with similar results. 
 
WB and MS results, showed in figure 23b and in table 4 respectively, allowed 
us to confirm Nucleolin/12 interaction. 
Table 4. Max Quant-based data analysis. Control and treated (5 µM 12) samples.*  
 
*Data are representative of at least two different experiments with similar results. 
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2.2.4 MS-based identification of further targets of 6,19-dihydroxy-ent-
trachiloban-17-oic acid  
In order to further investigate the mechanism of action of 12, a detailed 
analysis of DARTS results analyzed by MS was implemented. Particularly, by 
analyzing results from several DARTS experiments (five in total) by Mascot 
Daemon Matrix Science software, we identified Nucleolin as main target, and 
also  ezrin and alpha-catenin (Table 5). These two targets are mainly involved 
in cell migration and cell adesion, and have been described as potential 
markers for metastatic cancer progression.
110
 In addition, Nucleolin takes part 
of cancer cells migration events as well. Indeed, there are several studies in 
literature that show the roles of Nucleolin in cell migration and invasion. 
Nevertheless,  nowadays there is no evidence in literature that there could be a 
possible interaction or cooperation among Nucleolin, Ezrin and α-Catenin in 
this process. Some studies implied that the reduction of Nucleolin levels 
(transfecting cells with nucleolin-targeted small interfering RNA) in cancer 
cells could inhibit the process of epithelial mesenchymal transition (EMT) 
which enhances their metastatic potential. Yang et al showed that si-Nucleolin 
treatment attenuated the expression of p-Erk1/2, p-Akt, vimentin, N-cadherin, 
and MMP2, leading to decreased migration and invasion of gastric cancer 
cells.
111 Therefore, since Nucleolin is invoved in cell migration and it is able to 
interact with 12, these informations prompted us to investigate a possible 
modulation of compound 12 in these Nucleolin-madiated process.   
Table 5: Putative targets identified for 6,19-dihydroxy-ent-trachiloban-17-oic acid. DARTS 
experiment were performed at least five times, and the number of times each protein was 
identified is reported. 
Protein name number of 
times 
Nucleolin OS=Homo sapiens GN=NCL 4 
Ezrin OS=Homo sapiens GN=EZR 3 
Catenin alpha-1 OS=Homo sapiens GN=CTNNA1 3 
Data are representative of at least five different experiments with similar results. 
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2.2.5 Investigation of 6,19-dihydroxy-ent-trachiloban-17-oic acid activity 
in the cell migration: Wound Healing Assay 
On these bases, the involvement of 12 in cancer cell migration by Wound 
Healing Assay was evaluated. After treatment of HeLa cells with 12 (20 µM 
for 48h), a 1-mm wide scratch was made across the cell layer using a sterile 
pipette tip. After washing with PBS, DMEM medium was added to replace 
matrix depleted with the scratch. Using LAS-EZ software, each plate was 
photographed immediately after scratching, and the healing process was 
monitored at the electronic microscope each hour up to 24h  at the identical 
location of initial image. The distance between each side of the scratch was 
measured in pixels. As shown in figure 24, at 24h the cell migration for HeLa 
treated with 12 increased only for 25%, whereas for the control the migration 
increased up to 45%. Therefore, achieved results demonstrated a reduction of 
migration (20%) of HeLa cells induced by the treatment with the diterpene.  
 
Figure 24: Wound Healing assay on HeLa cells. a) Percentage of wound closure induced after 
treatment of HeLa cells with DMSO (control) and  20µM 12. b) Photografic monitor at time 0 
and after 24h from the scratch. Data are representative of at least two different experiments 
with similar results. 
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2.2.6 Biological effect of 6,19-dihydroxy-ent-trachiloban-17-oic acid on 
Nucleolin into the cell  
The evidence that 12 binds Nucleolin allowed us to further investigate the role 
of this diterpene in the modulation of Nucleolin-mediated processes in the 
cells. Most of them are mediated by Nucleolin in its  phosphorylated form. In 
fact, phosphorylation is one of the most important post-traslational 
modifications of Nucleolin, playing a crucial role in its translocation from the 
nucleolus to the plasma membrane.
39,40
 In this frame, we decided to verify the 
biological relevance of the binding of 12 to Nucleolin and p-Nucleolin. Firstly, 
we evaluated the levels of this protein, its fragmentation and phosphorylation 
in cell lysates following incubation of HeLa cells with  DMSO (control), 
oridonin 5 µM (used as negative control because from previous results we 
demonstrated that oridonin does not modulate Nucleolin and p-Nucleolin 
levels
19
) and 20 µM 12 for 4h, 8h and 16h and then underwent protein 
extraction procedure using RIPA buffer. WB results (Fig. 25) showed a 
moderate reduction of Nucleolin levels; in addition, a time-dependent 
reduction of p-Nucleolin was observed. This result led us to seek for further 
Nucleolin functions which our compound  could modulate.   
 
Figure 25: Treatment of HeLa cells with oridonin (5 µM, negative control) and  12 (20µM) 
up to 16h and evaluation of proteolytic fragments of Nucleolin in cell. The blots are 
representative of at least two different experiments with similar results. 
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2.2.7 6,19-dihydroxy-ent-trachiloban-17-oic acid activity in subcellular 
compartments 
As mentioned above, Nucleolin is not only located in the nucleolus, but also in 




 This  different localizations are 
due to changes in Nucleolin post-translational modifications, specially 
phosphorylation.
39,40
 In fact, Nucleolin translocation improves into the nucleus 
when it is dephosphorylated and enhances into the cytoplasm when 
phosphorylated. These results therefore indicate that the changes in the 
phosphorylation state of Nucleolin during the cell cycle might be a possible 
regulatory element of Nucleolin localization.
40
 Moreover, Hsp70 has been 
shown to regulate the phospho-Nucleolin translocation (through its RNA 
binding domains 3 and 4) to the cell surface (Fig. 26),
65
 where it becomes 
tumor receptor. According to this, the simultaneous inhibition of Hsp70 and 
Nucleolin functions by Oridonin and 12 in different cell compartments could 
lead to the decrease of several anti-apoptotic and proliferation signal 
pathways, crucial for cancer cell survival. 
 
Figure 26. Illustration of Nucleolin phosphorilation and traslocation to the plasma membrane 
mediated by Heat Shock Protein 70. 
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To obtain the subcellular compartments, HeLa cells were incubated with 
DMSO (control), oridonin 5 µM and  20 µM  12 for 4h at 37 °C. After 
obtaining nucleus, cytosolic and plasma membrane extracts, each lysate was 
fractioned by SDS-PAGE and the proteins were immunoblotted on a 
nitrocellulose membrane with antibodies specific for each cell compartment.  
As shown in figure 27, after 4h we can observe: 
- no modulation of nucleolar Hsp70, Nucleolin and phospho-Nucleolin 
levels; 
- reduction of cytoplasmatic phospho-Nucleolin and Hsp70 levels 
induced by 12;  
- high reduction of cell-membrane Hsp70 and phospho-Nucleolin  levels 
induced by oridonin and 12;  
 
Figure 27. Effect of oridonin and 12 on Nucleolin, p-Nucleolin and Hsp70 levels in nucleus, 
cytosol and plasma membrane. Western Blot analysis in HeLa cells treated with DMSO (ctrl), 
oridonin (5 µM) and 12 (20 µM) for 4h. For each immunoblot, band intensity was quantified 
by densitometry (numbers above each lane). α-Tubulin was included as a loading control for 
cytosol extracts, Lamin A for the nucleus extracts, Caveolin for plasma membrane extracts.  




2.2.8 RTq-PCR and Western Blot analyses  
Nucleolin is highly expressed in proliferating cells, including stem cells and 
cancer cells. Cancer cells acquire a number of features in order to become 
malignant, including the abilities to grow and proliferate, overcome 
senescence, evade apoptosis and the immune system, invade and metastasize 
other tissues and promote angiogenesis.
19
 Nucleolin through its RNA binding 
activity, conferred by its four RNA binding domains, could affect these traits. 
In fact,  the expression of several proteins involved in the survival of 
malignant cells during cell damage are modulated by Nucleolin. Specifically, 
this protein affects mRNA turnover by interacting with the 3'-untranslated 
region of several target mRNAs. In particular, we paid attention on the anti-
apoptotic proto-oncogene Bcl2, and on the pro-survival protein AKT1. Indeed, 
Nucleolin binds to Bcl2 mRNA and promotes the expression of Bcl2, 
increasing apoptosis in cancer cells, and also interacts with AKT1 mRNA, 
enhancing the translation of AKT1 
73, 74
 On this basis, we decided to verify the 
effects of 12 on the levels of these specific mRNAs.  
HeLa cells were treated with DMSO (control), oridonin (5 µM, positive 
control) and 12 (20 µM) for 4h and 8h and the stabilization of Bcl2 and AKT1 
mRNAs by Real-Time Quantitative Polymerase Chain Reaction (rtq-PCR) 
was evaluated. In figure 28a (left side, treatment with 12) we can observe a 
reduction in a time-dependent manner (22% of Bcl2 mRNA after 4h and 26% 
after 8h and 40% of AKT mRNA after 8h). Our WB results (figure 28b) 
confirmed the effect of 12, showing moderate decrease of AKT1 levels at 4h 




Figure 28: RTq-PCR of AKT1 and Bcl2 mRNAs HeLa cells, treated with 12 20µM (a) and  
oridonin 5µM (b) at 4h and 8h; c). WB of AKT1 and Bcl2 levels  HeLa cells  treated with 12 
20µM.  
2.2.9 Inhibition of Protein Synthesis  
Nucleolin plays a critical role in several steps of ribosome biosynthesis;
66
 this 
protein is indeed involved in rDNA transcription,
68
 is associated with nascent 
pre-rRNAs, helps assembly, and transport of ribosomal particles,
77
 as reported 
in paragraph 2.1.2. Consequently, Nucleolin interaction with compound 12 
could have dramatic effects on protein synthesis. On this basis, we monitored 
protein neo-synthesis in control cells and in cells after incubation with  12 (20 
μM) for 5h. Cycloheximide, a well-known inhibitor of the protein synthesis, 
was used as positive control, whereas DMSO was the negative one. Following 
incubation, the samples were treated with Click-iT® OPP (O-Propargyl 
Puromycin), a puromycin analog readily taken up by actively growing cells, 
which inhibits protein synthesis by disrupting peptide transfer on ribosomes 
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and causing premature chain termination during translation. Addition of the 5-
fluorescein azide and the click reaction reagents led to a chemoselective 
ligation between the azide dye and the alkyne OPP, allowing the modified 
proteins to be detected. Finally, all the samples were analyzed by flow 
cytometry. As depicted in Figure 29, cells treatment with the compound 
(highlighted in green) was comparable with the treatment with DMSO 
(control). This result demonstrated that 6,19-dihydroxy-ent-trachiloban-17-oic 
acid  did not affect the protein synthesis. 
Therefore, we could speculate on the involvement of 12 in Nucleolin-mRNA 
interaction  pathways,  whereas it is not involved in Nucleolin-mediated 
ribosome biogenesis pathways. 
 
Figure 29: Compound 12 effects on protein synthesis and cell cycle progression. HeLa cells 
were treated with vehicle (red), 50 μg/mL cycloheximide for 30 min (black), or 12 (20 μM) 
for 5 h (green). Cells were then incubated with OPP. 
2.2.10 Nucleolin(RBD1-2) expression and purification 
Once identified the biological effect of 6,19-dihydroxy-ent-trachiloban-17-oic 
acid in HeLa cells on Nucleolin, Bcl2 and AKT1 levels, our next goal was to 
study more in detail the Nucleolin/12 complex, in particular the binding site of 
the interaction. Serin et al. in 1999 studied the molecular mechanism of action 
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of Nucleolin when bound to mRNAs with its RNA-binding domains.
112
 As 
mentioned  in pharagraph 2.1, they discovered  that the presence of the first 
two RNA binding domains of Nucleolin (called RBD1-2) was crucial for the 
interaction with RNAs; in fact, if one of them is missing, no interaction with 
RNAs is observed. Furthermore, their activity could be cooperated by the 
GAR C-terminal domain.
77
 In addition,  RBD 3 and 4 are  not necessary for 
the binding with RNAs, since they are mostly specialized in Nucleolin 
translocation to the cell membrane.
65
   Based on this report, our next goal was 
to validate our results of reduction of ATK1 and Bcl2 mRNAs. In fact, a 
possible binding between 12 and Nucleolin (RBD1-2) could prevent its 
interaction with AKT1 and Bcl2  mRNAs, allowing us to link our data.     
Therefore, during my six months exchange PhD training at the Biomolekulares 
Wirkstoffzentrum (BMWZ), Leibniz University (Hannover, Germany) in the 
research group of Prof. Teresa Carlomagno and in collaboration with Prof. 
Anna Maria D‘Ursi, an expression and purification protocol specific for 
Nucleolin (RBD1-2) was adopted.
113
 A stab culture of BL21 (DE) plysS cells, 
containing the plasmid encoding for Nucleolin (RBD1-2), was provided.   
As shown in figure 30, Tuner cells showed better expression conditions than 
BL21 without mutation, indeed Tuner cells were selected for Nucleolin 
purification. 
 
  Figure 30. Optimization of Nucleolin (RBD1-2) expression conditions.  
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Therefore, Tuner cells were lysed by sonication for 20min. After 
centrifugation (1h at 19,000 g), the supernatant was filtered, added to a 
superloop connected to a His-trap FF Column (5mL) and analyzed by GE 
ÄKTA FPLC™ (Figure 31).   
 
Figure 31. His-Trap purification of Nucleolin (RBD1-2). 
 
Subsequently, protein fractions were collected, concentrated and analyzed by 
Gel Filtration using a S75 column (figure 32a). The final concentration 
(28mg/L of LB) was estimated with Bradford reagent (Bio-Rad protein assay) 
and checked by SDS-polyacrylamide gel electrophoresis (Figure 32b). 
        
 
Figure 32. a) Size Exclusion purification of Nucleolin (RBD1-2); b) Final SDS-PAGE of 




Once expressed and purified Nucleolin (RBD1-2), the next step was to test on 
these two domains oridonin and 12, and  to perform a screening of diterpenes 
with similar scaffold to oridonin and 12. The screening was implemented by 
different cell-free tecniques: Saturation Transfer Difference NMR (STD-
NMR), WaterLOGSY and Surface Plasmon Resonance (SPR).   
2.2.11 Screening of diterpenes against Nucleolin (RBD 1-2) by Saturation 
Transfer Difference NMR (STD-NMR) 
The first screening was peformed by STD-NMR against Nucleolin (RBD1-2), 
using a small library of thirteen diterpenes, most of them with the same 
trachilobanic scaffold of compound 12 (figure 33).  
 
Compound R R1 R2 R3 R4 
1 -CH3 -CH2OH H -CH2OH OH 
2 -CH2OH -CH2OH H -CH3 OH 
3 -CH2OH -CH2OH  -CH3 H 
4 -CH3 - CH2OH  -CH2OH OH 
5 -CH3 - CH2OH  -CH3 OH 
6 -CH2OH -CH2OH  -CH3 OH 
7 -CH3 - CH2OH  -CH3 OH 
 








Figure 33. Structures of diterpenes screened against Nucleolin RBD 1-2 by STD-NMR. 
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The STD-NMR experiment is a spectroscopic technique used to study 
interactions, in solution, between a large molecule (protein) and a medium-
small sized molecule (ligand).
32
 It is based on the Nuclear Overhauser effect 
and on the observation and analysis of the resonances of the ligand protons. 
In order to start our screening by STD-NMR, the best conditions of saturation 
for Nucleolin RBD1-2 were set up. Therefore, we recorded a 
1
H-NMR 
spectrum with only Nucleolin (RBD1-2) at high concentration (150 µM, figure 
34a) in order to see protonic signals. Subsequently, at the protein sample 
oridonin 1mM was added (figure 34b). As shown in figure 34b, we decided to 
irradiate the protein signals at 8.4 ppm, because of the lack of the ligand 
signals which could not undergo saturation. In fact, we could not irradiate the 
protein signals from 0 to 1ppm because they were overlapped with the ligand 
signals. In addition, irradiations with Gaussian and Adiabatic shape pulses 
were carried out (figure 34c and d). Particularly, the Adiabatic pulse was 





Figure 34. Optimization of STD-NMR. a) 
1
H-NMR spectrum of Nucleolin (RBD 1-2) 150 
µM. b) 
1
H-NMR spectrum of Nucleolin (RBD 1-2) 150 µM and oridonin 1mM. c) 
1
H-NMR 
spectrum of Nucleolin (RBD 1-2) 150 µM saturated in Adiabatic-shape. d)
 1
H-NMR spectrum 
of Nucleolin (RBD 1-2) 150 µM saturated in Gaussian-shape. 
 
Once optimizing the best conditions of saturation for Nucleolin (RBD1-2), 
samples in ratio ligand:protein 100:1 (1mM:10µM) were prepared. Achieved 
spectra led us to assert that compounds 5, 7 and 8 showed STD effect (figure 
35a, b and c respectively). In fact, in the STD spectra (in figure 35a in green, 
35b in red, 35c in blue) we could observe intense STD signals (highlighted 
with green circles) in the range from 0 to 2 ppm. Oridonin and 12 did not show 
interaction by STD-NMR. This could depend on two reasons: 
-  it was not possible to see STD-signals because there was a 
stable  interaction (KD in the nM range or covalent interaction);  
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- there was interaction but the signals of the protons of the 
ligand undergo saturation such as the ones of the protein, 
causing no NOE effect and no transfer of magnetization.  
 
 Figure 35. a) 1H-NMR off-resonance (in red), on-resonance (in blue ) and STD-NMR 
spectrum (in green) of Nucleolin (RBD1-2):5 in comparison; b) 1H-NMR off-resonance (in 
blue) and STD-NMR spectrum (in red) of Nucleolin (RBD1-2):7; c) STD-NMR spectrum (in 
blue) of Nucleolin (RBD1-2):8. 
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2.2.12 Screening of diterpenes against Nucleolin (RBD 1-2) by 
WaterLOGSY 
In order to validate and elucidate our STD results, we performed a second 
screening on the same collection of diterpenes. We decided to perform also 
WaterLOGSY experiments because STD-NMR can show some limitations, 
such as the effect of saturation which can be  inferred not only on the protons 
of the protein, but also on the protons of the ligand, resulting in lack of STD-
NMR signals. This problem can be overcome using WaterLOGSY (figure 
36).
33
   
 
Figure 36. a) WaterLOGSY principle; b) WaterLOGSY spectrum in comparison with Normal 
1D 
1




WaterLOGSY is a widely applied 1D ligand-observation technique for the 
detection of protein–ligand interactions. As the STD approach, WaterLOGSY 
is based on the NOESY experiment, and implies transfer of magnetization via 
a intermolecular NOE and spin diffusion. The originality of WaterLOGSY 
comes from the intervention of water molecules in the transfer pathway (Fig. 
36a). The bulk water magnetization is excited and transferred during the 
NOESY mixing time to the bound ligand.  
Small molecules that only interact with bulk water (non-binders) will 
experience much faster tumbling, which translates into a positive NOE (Fig 
36b Normal 1D spectrum). Therefore, opposite signs for signals from free 
versus protein-bound ligands are observed in a WaterLOGSY spectrum, which 
enables one to easily discriminate binders and non-binders. 
In our experimental conditions, a ratio ligand/protein 100:1 was set up for each 
sample. The WaterLOGSY results allowed us to confirm  compounds 5, 7 and 
8 interaction with (RBD1-2) Nucleolin domains  (figure 37 a,b and c). Indeed, 
intense negative NOE signals can be observed in the range 0-2 ppm, whereas 




Figure 37. Water-LOGSY experiment. a) Water-LOGSY spectrum of Nucleolin (RBD1-2)/5 
(10µM:1mM). b) Comparison between 1H NMR spectrum of  7 (in blue) and Water-LOGSY 
spectrum of Nucleolin (RBD1-2)/7 (10µM:1mM) (in red). c) Water-LOGSY spectrum of 
Nucleolin (RBD1-2)/8 (10µM:1mM). 
 
Interestingly, also 1 and 2 showed Water-LOGSY effect, observing intense 
negative NOE signals always in the window 0-2 ppm (figure 38a and b, 
respectively). The reason why no STD effect for these compounds was 
observed, can be explained with the effect of saturation inferred on the protons 
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of the ligand whose signals are close to 8 ppm. In Water-LOGSY experiment 
this problem is overcome, since there is no saturation process on the protein. 
No interaction was observed with oridonin or 12: this result led us to suppose 
a possible covalent binding between these two diterpenes and Nucleolin.  
 
Figure 38. Water-LOGSY experiment. a) Comparison between 1H NMR spectrum of  1 (in 
blue) and Water-LOGSY spectrum of Nucleolin (RBD1-2)/1 (10µM:1mM) (in red). b) 
Comparison between 
1
H NMR spectrum of  2 (in blue) and Water-LOGSY spectrum of 
Nucleolin (RBD1-2)/2 (10µM:1mM) (in red). 
 
2.2.13 Diterpenes/Nucleolin (RBD 1-2) interaction  by SPR 
To further investigate on a possible diterpenes/Nucleolin (RBD 1-2) covalent 
interaction, SPR experiments by Biacore technology were implemented. 
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Therefore, 1 μM Nucleolin (RBD1-2) in sodium acetate 50 mM, pH 4.16 was 
opportunely immobilized on a CM5-sensor chip, and the diterpenes were 
dissolved in PBS buffer in concentrations ranging from 10nM up to 4000nM 
and injected over the enzyme-modified chip. Compounds 1, 2, 5, 7 and 8 
showed interaction with Nucleolin (RBD1-2) with thermodinamic costants 
lower than 1µM. Achieved SPR results were in agreement with previously 
described WaterLOGSY results (Table 6).  
Table 6. Thermodinamic constants measured by SPR for the interaction 
between tested compounds and immobilized Nucleolin (RBD1-2). 
Compound KD (nM) ± SD ka [1/(nMxs)] kd (1/s)x10
-3
 
1  660 ± 0.5 10 ± 2 6,6 ± 0.1 
2   487 ± 0.3 82 ± 7 40 ± 1 
5   308 ± 0.1 39 ± 5 120 ± 3 
7  570 ± 1 100 ± 11 57 ± 0.5 
8  3750 ± 2 20 ± 6 750 ± 2 
 
According to our last results, for compound 12 and oridonin no interaction 
with Nucleolin (RBD1-2) was observed by SPR. This result allow us to assert 
that these two diterpenes probably esplicate their inhibition by binding to other 
domains of Nucleolin, such as  the C-terminal GAR domain. Indeed, as 
mentioned above, one function of the GAR domain could be to facilitate the 
interaction of Nucleolin RBD domains with targets located within large and 
complex RNA.
49,50 For these reasons, our next goal will be to test our 
compounds against other domains of Nucleolin. 
2.2.14 Conclusions 
Taken togheter, our results suggest 6,19-dihydroxy-ent-trachiloban-17-oic acid 
as a reasonable starting point to obtain small-molecules able to modulate 
Nucleolin activity. The present discovery might lead to new pharmacological 
tools to study Nucleolin and Nucleolin-mediated phatologic pathways.  
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Finally, this compound might represent a promising probe to study more in 
depth the biology of this protein in cancer cells. 
Materials and methods 
 
2.3 Determination of the apparent melting curve (Tm) of Nucleolin in 
HeLa cells by Cellular Thermal Shift Assay (CETSA).  
Approximately 5 × 10
6
 of Hela cells in a final volume of 10 mL of growth 
media were used for each condition (DMSO, positive control and treated) in a 
p100 Petri plate. A stock solution of oridonin (positive control) and of 12 (10 
μL of a 20 mM in DMSO) were added to each Petri plate to get a final 
concentration of 20 μM (0.1% DMSO); 10 μL DMSO was used as control. 
Cells were gently mixed by pipetting up and down at least 3 times and were 
incubated for 1 h up to 2 h in the CO2 incubator at 37 °C. Afterwards, the cell 
suspensions were collected and centrifuged in 15 mL conical tubes. Cell 
pellets were washed with PBS and gently suspended each pellet in 1 mL of 
PBS supplemented with protease inhibitors. Each cell suspension (DMSO, 
prositive control and treated) was divided into 8 different tubes and heated in a 
PCR machine (Invitrogen Life Science Technologies) at different temperatures 
(38.4, 41.3, 45.5, 49.8, 52.8, 55.6, 59.8, 61.3 °C) for 3 min. After heating, 
tubes were kept at R.T. for 3 min and then immediately snap-freezed in liquid 
nitrogen. After that, cell lysate–containing tubes were centrifuged at 20,000 g 
for 20 min at 4 °C to pellet cell debris together with precipitated and 
aggregated proteins. Each supernatant (10 μL) underwent WB analysis using 
anti-Nucleolin (rabbit polyclonal, ab22758; Abcam, Cambridge, UK) and anti-
GAPDH (rabbit polyclonal, sc-25778; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) antibodies. Cell whole lysates for immune-blotting analysis were 
prepared according to the standard protocol. Protein concentration was 
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determined by DC Protein Assay (Bio-Rad, Berkeley, CA, USA), using BSA 
as a standard. Proteins were fractionated on SDS-PAGE, transferred into 
nitrocellulose membranes, and immune-blotted with appropriate primary 
antibodies. Signals were visualized with appropriate horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence 
(Amersham Biosciences-GE Healthcare, NY, USA). Densitometry of bands 
was performed with ImageJ software. The achieved results were plotted on 
graphs reporting the ratio between the density measured for each Nucleolin 
band and the density measured for the corresponding GAPDH band. The 
density measured for cells kept at 38.4 °C was set as 100%.  
2.3.1 Determination of the EC50 of the complex (ITDRFCETSA) 
 Equal number of HeLa cells (5 × 10
5
 cells/well) were seeded in 12 well cell 
culture plates in 1 mL of growth media ad exposed to different concentrations 
of 12 (0.1, 0.5, 1, 2, 5, 10, 15 and 20 μM) for 2 h. Following the incubation, 
the drug-containing media were removed by centrifugation; cells were washed 
with PBS and prepared for CETSA experiment. In this case cells were heated 
at 55.5 °C (Tm of Nucleolin) for 3 min, and the experiment was performed as 
described above. In this case, the density ratio Nucleolin/GAPDH measured at 
Nucleolin concentration producing the maximum stabilizing effect (20 μM) 
was set as 100%. 
2.3.2 Drug Affinity Responsive Target Stability (DARTS) experiment  
HeLa cells were lysed in RIPA buffer  (10 mM Tris-Cl pH 7.6, 1 mM EDTA, 
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 
mM PMSF)  supplemented with protease and phosphatase inhibitors. Protein 
concentration was determined by DC Protein Assay (Bio-Rad, Berkeley, CA, 
USA), using BSA as a standard. Lysates (30 μg) were incubated with DMSO 
(control), or 12 20µM and 5µM (to obtain the final concentration of 20μM and 
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5μM and 0.1% DMSO). The samples were incubated for 2h at R.T. After that, 
the samples underwent proteolysis with subtilisin (enzyme: lysate 1:6000 w/w) 
for 30 min; hydrolysis was stopped adding Laemmli buffer 4X and incubating 
the mixture at 100 °C for 5 min. Finally, the samples were loaded in duplicate 
in two 10% mono dimensional SDS-PAGE gels, in order to perform at the 
same time MS and WB analyses.  
The first gel was treated with Fixing solution (MeOH:CH3COOH:H2O 4:1:5) 
for 30 min and then stained with Brilliant Blue G-Colloidal (Sigma-Aldrich) 
overnight. After washing with water, Bands appearing more intense in the 
treated samples than in the control ones were excised from both the gel lanes 
and subjected to classical in gel digestion procedure by tripsin (Promega, 
Milano, Italy). The resulting fragments were extracted and analyzed by 
LC/MS/MS.  MS and MS/MS data were used by Max Quant and Mascot 
Daemon Matrix Science softwares. The proteins detected in treated samples 
but not in controls were taken into account as possible 12 targets.  This 
DARTS experiment was performed in triplicate.  
The proteins on the second gel were transferred into a nitrocellulose 
membrane, and immunoblotted with the appropriate primary antibody 
(1:1000). Signals were visualized with the appropriate horseradish peroxidase-
conjugated secondary antibody and enhanced chemiluminescence (Amersham 
Biosciences-GE Healthcare, NY, USA). Densitometry of bands was performed 
with ImageJ software. 
A similar procedure was performed to carry out DARTS on living cells. HeLa 
cells (5 × 10
6
 cells/well) were treated with 12 (5 or 20 µM)  or 0.1% DMSO 
for 2 h at 37 °C. Cells were lysed with RIPA buffer (10 mM Tris-Cl pH 7.6, 1 
mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 
mM NaCl, 1 mM PMSF) supplemented with protease and phosphatase 
inhibitors (P8340, Sigma-Aldrich, St. Louis, MO, USA). After centrifugation 
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and determination of protein concentration, each lysate (30 μg) was diluted 
with PBS, quickly warmed to R.T. and proteolysed with subtilisin (enzyme: 
lysate 1:6000 w/w) for 30 min. Reaction mixture was then analyzed as 
described above. Also in this case, DARTS experiment was performed in 
triplicate, and the proteins identified in all the experiments were considered 
putative 12 targets. 
2.3.3 Wound Healing assay 
Equal number of HeLa cells (3 × 10
5
 cells/points) were seeded in a 6 well cell 
culture plates in 1 mL of growth media (DMEM high glucose with glutamine, 
10% FBS, 1% pen/strep). After 24h they were treated with 12 20 μM or 0.1% 
DMSO (control).  After incubation for 72h at 37°C, a 1-mm wide scratch was 
made across the cell layer using a sterile pipette tip. After washing with PBS, 
DMEM medium was added to replace matrix depleted with the scratch. Using 
LAS-EZ software, each plate was photographed immediately after scratching, 
and the healing process was monitored at the electronic microscope each hour 
up to 24h  at the identical location of initial image.  For each scratch 4 
measurements (distance between two sides of the scratch measured in pixels)  
were carried out, and the difference between the cell migrations after 1h and 
24h of incubation with DMSO (control) or 12 was calculated. All experiments 
were performed at least two times in triplicates.  
2.3.4 RNA isolation and quantitative Real-Time-PCR (qRT-PCR) 
Total RNA was isolated using Trizol Reagent (Life Technologies, Grand 
Island, NY, USA) according to the manufacturer‘s instructions and 
spectrophotometrically quantified. RNA integrity was assessed by agarose gel 
electrophoresis. RNA (3 μg) was reverse transcribed, and real-time PCR was 
performed with Light-Cycler® 480 (Roche Diagnostics GmbH, Mannheim, 
Germany) using SYBR Green detection in a total volume of 20 μL with 1 μL 
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of forward and reverse primers (10 mM) and 10 μL of SYBR Green I Master 
Mix (Life Technologies). Reactions included an initial cycle at 95 °C for 10 
min, followed by 40 cycles of denaturation at 95 °C for 10 sec, annealing at 56 
°C for 5 sec, extension at 72 °C for 15 sec. The 18S RNA was used as an 
internal standard. The following primer sets were used for real-time PCR to 
assay specific mRNAs: 
forward Akt 5′-TCT ACA CCC ACA GAT GAC AG-3′ 
reverse Akt 5′-CTC AAA TGC ACC CGA GAA AT-3′ 
forward Bcl-2 5′-GGA AGT GAA CAT TTC GGT GAC-3′ 
reverse Bcl-2 5′-CTC CAT CAG CTT CCA GAC AT-3′ 
forward 18S 5′-CGA TGC TCT TAG CTG AGT GT-3′ 
reverse 18S 5′-GGT CCA AGA ATT TCA CCT CT-3′ 
 
2.3.5 Protein Synthesis assay 
HeLa cells (4x10
5 
cells/well) were incubated with 12 (20 μM for 5h), 
respectively, or with 50 μg/mL cycloheximide (CHX) for 30 minutes, in a cell 
culture incubator. Cells were then processed for detection of protein synthesis 
according to the protocol described in the Protein Synthesis Assay Kit 
(Cayman Chemical, Michigan, USA). Following incubation, the samples were 
treated with Click-iT® OPP (O-Propargyl-Puromycin), and added of 5-
fluorescein azide, the click reaction reagents leading to a chemoselective 
ligation between the azide dye and the alkyne OPP, allows the modified 
proteins to be detected. Finally, all the samples were analyzed by flow 
cytometry. 
2.3.6 Cell viability and cell cycle analysis 
The number of viable cells was quantified by MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] assay. Absorption at 550 nm was 
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assessed using a microplate reader (LabSystems, Vienna, VA, USA). Cell 
viability was also checked by Trypan Blue exclusion assay using a Bürker 
counting chamber.  
Cell cycle was evaluated by propidium iodide (PI) staining of permeabilized 
cells according to the available protocol,
109
 and flow cytometry (BD 
FACSCalibur flow cytometer, Becton Dickinson, San Jose, CA, 
USA). Data from 5000 events per sample were collected. The percentages of 
the elements in the hypodiploid region and in G0/G1, S and G2/M phases of the 
cell cycle were calculated using the CellQuest and MODFIT software, 
respectively. 
2.3.7 Determination of apoptosis  
HeLa cells (3x10
5
 cells/well) were incubated with DMSO (control),  (phenetyl 
isothiocyanate (PEITC, positive control) 10µM for 24h and 12 20µM for 48h 
in a cell culture incubator. Cells were then processed for detection of apoptosis 
according to the protocol described in the Annexin V, FITC Apoptosis 
Detection Kit (Dojindo EU GmbH, Munich (Germany)). Following 
incubation, HeLa pellets were washed twice with PBS and suspended in 
100µL of Annexin V Binding Solution; subsequently, 5µL of Annexin V, 
FITC conjugate and 5µL of PI Solution were added in each sample and 
incubated for 15 min at room temperature with protection from light. After 
adding 400µL of Annexin V Binding Solution, samples were detected by Flow 
Cytometry (BD FACSCalibur flow cytometer, Becton Dickinson, San Jose, 
CA, USA) and analyzed by  BD Facsuite software.   
2.3.8 Expression and purification of recombinant NCL (RBD1-2) 
Tuner  cells (BL21 (DE3) with a mutation in the lac permease (lacZY) gene) 
were transformed with recombinant pET15b plasmid containg the gene for 
Nucleolin (RBD1-2). Cells were grown at 37 °C in LB (100 mg/liter 
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ampicillin) at 200 rpm and induced with 0.1 mM isopropyl-1-thio-β-D-
galactopyranoside. After induction the cells were incubated overnight at 16 °C 
at 200rpm. The cells were harvested and resuspended in buffer A (Tris 50 
mM, NaCl 100 mM, 50% Glycerol, imidazole 10mM, β-mercaptoethanol 
5mM, pH 7,6) with DNase I (5 mg/ml), lysozyme and protease inhibitors 
(Complete EDTA-free tablets, Roche). The cells were then lysed by sonication 
for 20min and centrifuged. After centrifugation (1h at 19,000 g), the clarified 
cell lysate was loaded on a His-trap FF Column (5mL) and the His-tagged 
Nucleolin (RBD1-2) was purified using GE ÄKTA FPLC™. Subsequently, 
protein fractions were collected, concentrated and further purified by size 
exclusion chromatography using superdex75 16/600 column in buffer B 
(Na2HPO4 50mM, NaH2PO4 8mM, NaCl 150mM, pH 7.6). The concentration 
of the protein was estimated by mesuring absorbance at 280nm. SDS-
polyacrylamide gel electrophoresis was used to assess the purity of the protein. 
2.3.9 Ligand-binding NMR experiments 
NMR spectra to detect ligand-binding were recorded on a 600 MHz Bruker 
Avance III-HD spectrometer equipped with a cryogenic (nitrogen-cooled) 
inverse probe-head. Samples were prepared in phosphate-buffered saline 
(PBS) at pH 7.6, to which 10 % v/v D2O (Carlo Erba) was added for the NMR 
field-frequency lock.  Final samples with a volume of ~500 uL were 
transferred to 5-mm-diameter NMR tubes for measurement. All spectra were 
recorded at a temperature of 278 K.
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2.3.10 Saturation Transfer Difference NMR (STD-NMR) analysis 
The STD pulse-sequence consists of an extended period of RF irradiation to 
saturate the protein resonances followed by a read-out element (in this work, 
the 3-9-19 WATERGATE sequence was used as the read-out element). 
Saturation of the protein resonances was achieved with an adiabatic pulse-
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train; prior to acquiring the STD spectra, the parameters for the adiabatic pulse 
were first optimized on a sample of Nucleolin (RBD1-2) alone at a 
concentration of ~150 µM.  The final optimized adiabatic pulse was a 
constant-adiabaticity WURST-2 pulse with a pulse-length of 25 ms, a sweep-
width of 2 ppm and a B1 field-strength corresponding to an adiabaticity Q-
factor of 3 (v1,max = 247 Hz).  The saturation pulse-train was applied for the 
entire duration of the inter-scan recycle delay. STD spectra (256 scans with a 
recycle delay of 4 s and acquisition time of 1.3 s) were then recorded for 
samples of 14 ligands at a concentration of 1 mM in the presence of 10 µM 
Nucleolin (RBD1-2).  Each final STD spectrum is calculated as the difference 
between two sub-spectra in which the protein is either saturated (the "on-
resonance" sub-spectrum) or unsaturated (the "off-resonance" or reference 
sub-spectrum).  The two sub-spectra for each ligand were recorded in an 
interleaved fashion with identical parameters except for the transmitter 
frequency of the saturation pulse-train, which was positioned at 8.6 and 100 
ppm for the on- and off-resonance sub-spectra, respectively.
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2.3.11 WaterLOGSY experiment 
The water-LOGSY sequence consists of an initial e-PHOGSY element to 
destroy all non-water magnetization, a mixing period to allow magnetization-
transfer, and final read-out element (in this work, the excitation-sculpting 
sequence was used as the read-out element; this read-out element was 
preceded by a water flip-down pulse in order to preserve the water 
magnetization).  The water-selective refocusing pulse in the e-PHOGSY 
element was a 25-ms ReBURP pulse.  Two broadband-inversion-pulses were 
applied during the mixing period (at ~one-quarter and ~three-quarters of the 
mixing-time) to improve suppression of auto-relaxed signals. 
Water-LOGSY spectra (512 scans with a mixing time of 1 s, a recycle delay of 
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3 s and an acquisition time of 1.3 s) were recorded for 14 samples (1 mM 





2.3.12 Surface Plasmon Resonance (SPR) 
SPR studies were performed using an optical biosensor BIACORE 3000 (GE 
Healthcare, Milano, Italy). Nucleolin (RBD 1-2) (6 mg/ml) was immobilized 
on a CM5 sensor chip using a 1 μM protein solution in sodium acetate 50 mM, 
pH 4.16. using a standard amine-coupling protocol. All the compounds were 
dissolved in 100% DMSO to obtain 4 mM solutions, and diluted in PBS (10 
mM NaH2PO4, 150 mM NaCl, pH 7.4) to a final DMSO concentration of 
0.5%. The binding study was performed using a five-point concentration series 
(10, 100, 500, 1000 and 4000 nM) and triplicate aliquots of each compound 
concentration were dispensed into single-use vials. Binding experiments were 
performed at 25 °C, using a flow rate of 50 μL/min, with 60 s of association 
and 300 s dissociation monitoring time. Simple interactions were adequately 
fit to a single-site bimolecular interaction model, yielding a single KD. 
Sensorgram elaboration was performed using the BIAevaluation software 
provided by GE Healthcare. 
2.3.13 Western Blot analysis 
Cell whole lysates (HeLa) immunoblot analysis were prepared according to 
the standard protocol.  Protein concentration was determined by DC Protein 
Assay (Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as 
a standard. Proteins were fractionated on SDS-PAGE, transferred into 
nitrocellulose membranes, and immunoblotted with the appropriate primary 
antibody (1:1000). Signals were visualized with the appropriate horseradish 
peroxidase-conjugated secondary antibody and enhanced chemiluminescence 
(Amersham Biosciences-GE Healthcare, NY, USA). Densitometry of bands 
was performed with ImageJ software. 
88 
 
2.3.14 Reagents and Antibodies 
Fetal bovine serum (FBS) was from GIBCO (Life Technologies, Grand Island, 
NY, USA). The anti-Nucleolin (rabbit polyclonal, ab22758) and anti-phospho 
T76-Nucleolin (rabbit monoclonal) were purchased from Abcam, Cambridge, 
UK. Anti-pAkt (rabbit polyclonal sc-7935-R), anti-Akt (rabbit polyclonal), 
anti-Bcl2 (mouse monoclonal sc-7382),  anti-α-Tubilin (mouse monoclonal sc-
32293), anti-GAPDH (rabbit polyclonal), anti-caveolin (rabbit policlonal sc-
894), were obtained from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Inc., Delaware, CA, USA); anti-Lamin A (rabbit polyclonal, 
L1293) was purchased from Sigma-Aldrich (USA); appropriate peroxidase-
conjugated secondary antibodies were from Jackson Immuno Research 
(Baltimore, PA, USA).   
2.3.15 Cytosol and membrane extracts 
After incubation of HeLa cells with oridonin (5 μM) and 12 (20 μM) for 4h at 
37°C,   the cells were washed twice with PBS, detached with trypsin-EDTA 1x 
in PBS (Euroclone), harvested in PBS and centrifuged for 5 minutes at 600 x g 
at 4°C. After that, the pellets were resuspended in 4 mL of lysis buffer (Tris 
HCl 20 mM, pH 7,4; sucrose 250 mM; DTT 1 mM; protease inhibitors, EDTA 
1 mM in water), sonicated (5 seconds pulse - 9 seconds pause for 2 minutes, 
amplitude 42%) and then centrifuged at 4°C for 10 minutes, at 5000 x g. The 
obtained supernatants were ultra-centrifuged for 1 hour at 100000 x g at 4°C, 
until to get new supernatants that represent cytosol extracts. Each resulting 
pellet was resuspended in 4 mL of lysis buffer and ultra-centrifuged for 1 hour 
at 100000 x g at 4°C. The pellets were then resuspended in 250 µL of 
solubilization buffer (Tris HCl 20 mM, pH 7,4; DTT 1 mM; EDTA 1 mM; 
Triton X-100 1%, in water) and left overnight on orbital shaker at 4°C. After 
that, the solution was centrifuged for 30 minutes at 50000 x g at 4°C: the 
supernatants represent the membrane extracts.  
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2.3.16 Nuclear extracts 
HeLa cells were incubated with oridonin (5 μM) and 12 (20 μM) for 4h at 
37°C, then washed twice with PBS, detached with trypsin-EDTA 1x in PBS 
(Euroclone), harvested in PBS and centrifuged for 5 minutes at 600 x g at 4°C. 
The pellets were resuspended in 500 µL of buffer A (Hepes pH 7.9 10 mM, 
EDTA pH 8.0 1 mM, KCl 60 mM, N-P40 0.2%, DTT 1 mM, 
phenylmethylsulfonyl fluoride (PMSF) 1 mM, protease inhibitors) and then 
left on ice for 10 minutes. After that, the samples were centrifuged at 660 x g 
for 5 minutes at 4°C, resuspended in 50 µL of buffer B (Tris HCl pH 7.8 250 
mM, KCl 60 mM, DTT 1 mM, PMSF 2 mM, glycerol 20% v/v in PBS) and 
centrifuged again at 9500 x g for 15 minutes at 4°C. The obtained pellets were 
resuspended in 100 µL of buffer C (Hepes pH 7.9 10 mM, EDTA pH 8.0 1 
mM, KCl 60 mM, DTT 1 mM, PMSF 1 mM, protease inhibitors) and 
centrifuged at 660 x g for 5 minutes at 4°C. The samples were then washed 
twice with 1 mL of buffer C, resuspended in 50 µL of buffer B and exposed to 
3 cycles of freeze/thawing. Finally, the samples were centrifuged at 9500 x g 
for 15 minutes at 4°C: the surnatants represent the nuclear extracts. 
2.3.17 Statistical analysis  
Data are reported as the mean values ± SD from at least three experiments, 
performed in duplicate (n ≥6), showing similar results. Differences between 
treatment groups were analyzed by Student‘s t-test. Differences were 




























































































3.1 Heat Shock Proteins (HSPs) family 
 Stress or heat shock proteins (HSPs) are a family of highly conserved 
proteins, induced in response to a wide range of physiological and 
environmental insults such as hypoxia, hyperoxia, exposure to UV light and 
chemicals, viral agents, heavy metals, surgical stress, nutritional deficiencies 
(e.g. glucose deprivation), emotional and mechanical stress, or other stresses. 
They mantain cellular homeostasis under stress or allow the cell survival to 
lethal conditions.
115, 116
 Mammalian HSPs have been classified into six 
families depending on their molecular size: Hsp100, Hsp90, Hsp70, Hsp60, 
Hsp40 and small HSPs (15 to 30 kDa) including Hsp27. Family members of 
HSPs are expressed either constitutively or inductively, and are localized in 
different subcellular compartments. HSPs with high molecular weight are 
ATP-dependent chaperones, whereas small HSPs act in an ATP-independent 
way. As molecular chaperones, the function of HSPs is to regulate protein 
folding, transport, translocation and assembly, especially helping in the 
refolding of misfolded proteins or assisting in their removal, if they are 
damaged after various stresses or environmental insults.
117
 
Cancer cells, with higher metabolic requirements and more abundant signal 
transduction pathways than normal cells, need a higher amount of chaperones 
than normal cells in order to survive. Several studies have reported that 
overexpression of the HSPs increases tumor growth, metastatic potential, and 
resistance to chemotherapy in both human and animal models. Being involved 
in the folding and stabilization of relevant oncoproteins, HSPs stand at the 
crossroads of multiple oncogenic pathways. Therefore, inhibition of HSPs 
offers the unique advantage of depleting multiple oncoproteins affecting 
several pathways necessary for tumor progression.
118
 The most studied stress-
94 
 
inducible HSPs are Hsp90, Hsp70 and Hsp27, whose expression and/or 
activity is abnormally high in cancer cells and increases after many different 
death stimuli.
117
 They are powerful anti-apoptotic proteins, associating with 
key apoptotic factors (Fig. 1), and thereby blocking this cell death process at 
different levels.
119
 The inhibition of Hsp90, Hsp70 and/or Hsp27 represents an 
interesting strategy for cancer therapy.  
 
Figure 1. Hsp27, 70, 90 in the regulation of apoptosis and proliferation. Hsp27, 70 and 90 
regulate apoptosis at different levels, from the death receptors signaling to executors of cell 
death program, affecting both upstream and downstream of the death-associated mitochondrial 
pathways. Induction of caspases activation determines proteasome activation. Moreover, HSPs 
facilitate the degradation of proteins by the ubiquitin/proteasome system. Adopted form: 
Wang X  et al., Inter J Oncol.  2014; 45: 18-3.  
3.1.1 Heat Shock Protein 70 (Hsp70): structure, localizations and roles 
The Hsp70 family of molecular chaperones plays central roles in all the 
aspects of proteostasis, from protein folding to disaggregation and 
degradation.
120
 Hsp70 chaperones can interact with most proteins in their 
unfolded, misfolded or aggregated states, and can actively fold, solubilize, and 
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reactivate already formed, stable protein aggregates.
121
 With the help of its co-
chaperones, some Hsp70s recognize a limited set of native proteins, and 
regulate or even redefine their activity.
122
 Although the prokaryotic system has 
a single Hsp70 (the archetypical DnaK), the number of genes has expanded in 
eukaryotes, which express distinct Hsp70 isoforms in different physiological 
conditions and subcellular locations (Table 1). The human genome encodes 13 
Hsp70 isoforms; three are constitutively expressed, heat shock cognate protein 
(Hsc70 or HSPA8, which accumulates in cytosol and the nucleus), Bip 
(HSPA5 or 6RP78, endoplasmic reticulum) and mortalin (HSPA9 or 6RP75, 
mitochondrial). The expression of other Hsp70, particularly Hsp70-1 
(HSPA1A/B), is inducible (after cell stress).  
Table 1. Localization and isoforms of the Hsp70/Hsc70  
 
Apart from its intracellular localization, Hsp70 (also termed HSP70A1A) was 
found also on the plasma membrane, playing pitoval roles in eliciting anti-
tumor immune response. Shevtsov et al. determined a tumorselective Hsp70 
membrane expression, whereas a membrane Hsp70–positive tumour 
phenotype is associated with aggressiveness and therapy resistance. Therefore, 
membrane Hsp70 represents a recognition structure for targeted therapies, 
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Structurally, Hsp70 has two functional domains, connected by a short and 
highly conserved interdomain linker (Fig. 2): 
  The N-terminal Nucleotide-Binding Domain (NBD; 45 kDa) structurally 
shows an actin/hexokinase fold, having a V-shaped structure composed of two 
subdomains that enclose the ATP-binding site (Fig 2a in blue).  
 
                a                                      b  
Figure 2. a) cristal structure of HSP70; b) different conformations of SBD;  
Adopted from Kumar DP et al. 2011; J  Mol Biol. 411, 1099–1113. 
 
Both NBD subdomains and the connecting helixes create the binding pocket 




 ions at the bottom of the cleft (Fig 3). The 
nucleotide is positioned into the active site by interactions with two phosphate-
binding loops and a hydrophobic adenosine binding pocket, together with 
contacts with the Mg
2+
 ion, which is coordinated by several side chains  of 
Hsp70. McKay and coworkers have proposed a mechanism for ATP 
hydrolysis: structural rearrangement of Hsp70 during ATP binding leads to 
adjustement of the position of the -phosphate so that a bidentate complex is 
formed between the β and -phosphate oxygens and Mg
2+
, allowing the attack 
by a water (or OH
-
) which is hydrogen bonded to Lys-71 (Fig 3). Precise 
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geometry of the nucleotide and the surrounding residue requires the correct 
positioning of the Mg
2+







Figure 3. ATPase domain of Hsp70. Bound to it, ADP, Pi, Mg
2+
 (magenta), and two K
+
 ions 
(blue) are indicated. The backbone of phosphate binding loops 1 (residues 10–15) and 2 
(residues 199– 206) is indicated in red, and the side chains involved in positioning the 
phosphates of bound nucleotide and Mg
2+
 (including Lys- 71) are shown as green sticks. 
Adopted from Bukau B,  Horwich AL. 1998; Cell. 92: 351–366.  
 
 The C-terminal, Substrate-Binding Domain (SBD; 25 kDa), possesses two 
subdomains: a β-sheet domain (SBDβ, fig 2a in green) or base, and a α-helical 
(SBDα, fig 2a in red) or Lid domain. The SBD recognizes and interacts with a 
motif present every 30–40 residues in several proteins; it is a five-residue 
motif enriched in hydrophobic amino acids and positively charged residues.
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This type of hydrophobic region is usually found in the protein core, and its 
exposure signals a misfolded conformation. The SBD adopts two different 
conformations, the open and the closed ones; the switch between them is  
controlled by ATP binding to NBD (Fig. 2b). Indeed, the two functional 
domains have to be coupled to make a functional chaperone, which leads to 





The crystal structure of the substrate binding domain of Hsp70 shows a β 
sandwich composed of two sheets of four strands each, followed in the 
primary structure by two a helixes, A and B, which are prositioned back over 
the sandwich (Fig. 4). The top sheet emanates four loops, two of which form 
the substrate binding pocket, a channel with a cross section of 5 x 7 Å. Along 
with loops at either side, they are stabilized by critical contacts with the 
overlying helix B, which may function as a lid in permitting entry and release 
of substrate (without directly contacting it). The most extensive contacts are 
hydrophobic side-chain interactions between the loops and three central 
leucines in the peptide. In order to obtain these contacts, the bound region of 
the polypeptide must be substantially unfolded.
127
 
                            
Figure 4. Cristal structure of NBD and SBD domains of Hsp70. Adopted from Bukau B,  
Horwich AL. 1998; Cell. 92: 351–366. 
 
Hsp70 function is fine-tuned by the cooperation of a variety of cochaperones, 
which bind to Hsp70 and modulate its activity by increasing or decreasing the 
chaperone affinity for substrates, through the stabilization of the ADP or ATP 
bound state of Hsp70. They can be classified into three groups: 
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  The J-domain co-chaperones, like Hsp40, constitute a relatively large group 
of proteins that binds to the Hsp70 NBD and positively modulates the ATPase 
activity of this chaperone.  
  The nucleotide exchange factor (NEF) co-chaperones catalyze the release of 
ADP, required for the completion of the ATPase cycle. Members of this group 
are BAG-1, BAG-3, Hsp110, or HspBP1. 
  The TPR domain co-chaperones (Hop, CHIP) bind to the C-terminal EEVD 
motif presented in both Hsp70 and Hsp90. They are essential for 
combinational assembly of Hsp70 and Hsp90 complexes, required for the 
stabilization of Hsp90 client proteins.  





 J-proteins accelerate ATP hydrolysis and thus induce 
the achievement of the closed conformation, whereas NEFs promote ADP/ 
ATP exchange and the open conformation. Both groups interact with Hsp70 
through its NBD (Fig. 2b). The BAG proteins (Bcl-2-associated athanogene) 
are NEFs that use a conserved BAG domain to interact with the interface 
formed by NBD subdomains IB and IIB to promote nucleotide cycling.
130
 The 
C-terminal-most Hsp70 domain (CTD) bears an EEVD amino acid motif that 
interacts with distinct cochaperones, which in turn guide Hsp70- bound 
substrate towards folding or degradation.
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Hsp70 has a prominent role in the ATP hydrolysis cycle (Fig. 5). When ATP 
is bound to the NBD, it induces the open conformation by separating the base 
and Lid subdomains. In this conformation, the SBD is in contact with the NBD 
and has low affinity for the substrate. The Hsp70 closed conformation is 
achieved after ATP hydrolysis; the NBD induces a change in the SBD such 
that the base and Lid subdomains come closer together and trap the substrate. 
SBD structural rearrangements are transmitted from the NBD via a flexible, 
conserved linker that contacts the NBD in the open state, and detaches in the 
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closed conformation. Two types of cofactors control the cycling of this 
ATPase between the two conformations: the J chaperones and the NEF. 
Through the intermediary of the J domain, Hsp40 binds to Hsp70 and 
promotes its ATPase activity, thus generating the ADP-bound Hsp70, which 
stably interacts with client protein. After the nucleotide exchange factor (NEF) 





          Figure 5. Hsp70/Hsp40 ATP hydrolysis cycle. 
 
Heat Shock Protein 70 is involved in many physiological and pathological 
process, 
132
 such as: 
 preventing aggregation and assisting refolding of misfolded proteins; 
 assisting folding of some newly translated proteins; 
 guiding translocating proteins across organellar membranes acting 
at both the cis and trans sides; 
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 disassembling oligomeric protein structures; 
 facilitating proteolytic degradation of unstable proteins;  
 controlling the biological activity of folded regulatory proteins, 
including transcription factors; 
 cancer, autophagy, neurodegenerative diseases and aging; 
Hsp70 is abundantly expressed in many tumor types and it is accompanied by 
increased cell proliferation, metastases and poor response to chemotherapy. 
High expression of Hsp70 enhances the ability of the cancer cells to survive to 
a range of lethal conditions.
133
 The cytotoxic effect of Hsp70 down-
modulation is particularly strong in transformed cells, yet undetectable in 
normal, non-transformed cell lines or primary cells. This fact has been 
interpreted by assuming that tumor cells, as compared to their normal 
counterparts, exhibit a constitutively stressed phenotype with an enhanced 
dependency on the cytoprotective action of Hsp70. Hsp70 exerts the 
cytoprotective action probably through its ability to inhibit apoptosis. Gene 
ablation studies demonstrate that Hsp70 plays an important role in apoptosis. 
Indeed, Hsp70 suppresses apoptosis through inhibition of both intrinsic and 
extrinsic apoptotic pathways. Cells lacking hsp70.1 and hsp70.3, the two 
genes that code for inducible Hsp70, are highly sensitive to apoptosis induced 
by a wide range of lethal stimuli.
132, 133
 Hsp70 can regulate apoptosis at 
different levels from death receptors signaling to executors of cell death 
program, affecting both upstream and downstream of the death-associated 
mitochondrial events. Hsp70 also negatively interferes with MAPK family 






Figure 6. Hsp70 in apoptosis. Hsp70 plays a crucial role in the phosphorilation of MKP1, 
which avoids p38 and JNK1 phosphorilation. P-p38 and p-JNK1 lead to the activation of a 
cascade of signals which activate apoptosis.  
 
Studies indicated that Hsp70 inhibits the apoptosis induced by 
hyperosmolarity modulating JNK and ERK phosphorylation.
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 Hsp70 
contributes to the stabilization of the stress-activated kinases, such as AKT, 
binding to the non-phosphorylated kinase via the kinase carboxyl-terminus, 
priming the kinase for rephosphorylation and stabilizing the protein.
136
  
Several roles of Hsp70 in cancer initiation and progression are connected to its 
involvement in regulating cell signaling. Moreover, Hsp70 regulates multiple 
pathways in cancer cells via interaction with the co-chaperone BAG3, which 
may serve as a scaffold/mediator that transmits effects of Hsp70 to multiple 





3.1.2 Hsp70 inhibitors 
Since the involvment of Hsp70 chaperones in human deseases such as cancer,  
neurodegeneration and aging, searching for compounds able to target Hsp70 
has become a challenging goal in the last decades. Nowadays only a few 
modulators of  Hsp70 activity have been identified.
138-143
  
Hsp70 inhibitors can be classified in three basic categories:  
- small molecule inhibitors:  
A small molecule inhibitor called 2-phenylethylensulfonamide (PES) or 
pifithrin-μ interacts with the C-terminal SBD of Hsp70, disrupting the 
association between Hsp70 and cofactors such as Hsp40 and client proteins, 
including the pro-apoptotic proteins APAF-1, p53 and others. This takes to the 
aggregation of misfolded proteins, and to the destabilization of lysosome 
membranes, inducing cell death. PES has been proven as a potent antitumor 
agent.
138
 15-Deoxyspergualin (15-DSG Fig. 7), a natural immunosuppressive 
agent, disrupting Hsp70-ATP interaction through binding to Hsp70 and 
lowering its ATPase activity (25% of reduction), was the first compound 




Figure 7. Structure of 15-DSG  
 
VER-155008 is an adenosine-derived compound. It functions to inhibit the 
chaperone activity of Hsp70 and other family members by binding the ATPase 
domain. Azure C, methylene blue and myricetin have been idenitified as 
inhibitors of Hsp70 through a high-throughput screening for ATP turnover 
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mediated by human Hsp70, but their specificity for inducible Hsp70 family 
has not yet been analyzed.
140
 MKT-077, a cationic rhodacyanine dye, 
Apoptozole, Sphingolipids can also bind to the NBD of Hsp70 and specifically 
inhibit Hsp70 ATPase activity.
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- protein aptamers: The most potent aptamer, A17, binds to the NBD of 
Hsp70, and was demonstrated to disrupts the function of Hsp70 in a 
biochemical assay in vitro. A17 increases the sensitivity to apoptosis 
induction by anticancer drugs (cisplatin and 5-fluorouracil) and, in vivo, 
has a strong antitumor effect.
142
 
- antibody treatments: The most promising strategy reported for developing 
Hsp70 inhibitors utilizes the immune system, and it is the only Hsp70-
targeted therapy currently in clinical trials (clinicaltrials.gov). However, 
there are severe limitations due to the lack of tumor-specific markers 
related to Hsp70. However, a recently developed monoclonal antibody, 
cmHsp70.1, successfully recognizes the extracellular motif, 
TKDNNLLGRFELSG (TKD) of membrane bound Hsp70. Since only 
cancer cell moves Hsp70 to the membrane, while normal (non-
transformed) cells do not, the TKD motif represents an excellent tumor-
specific biomarker. CmHsp70.1 has successfully passed through a safety 
and efficacy phase I trial and it is currently in a phase II clinical trial for 
non-small cell lung cancer in combination with radio chemotherapy.
143
 
3.1.4 Aim of the project  
The knowledge of the mechanism of action of promising plant molecules is a 
required starting point for many pharmaceutical and biochemical researches. 
In this field, biochemical and proteomic-based studies play a central role, 
allowing to describe the possible modulators of a selected protein target. In 
order to investigate the mechanism of action of our bioactive diterpenes, a 
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Reverse Chemical Genetics (RCG) approach was adopted. In this study we 
carried out: 
-  the screening of a library of bioactive kauranes and kaurane-derivatives 
against Hsp70, to identify the best ligand by Surface Plasmon Resonance 
(SPR).  
- Hsp70/ligand interaction validation through:  
         *  cell-free assays: LC/MS, peptide mapping, ATPase activity assay, 
molecular docking. 





























Results and discussion 
 
3.2 Identification of  Hsp70 ligands by Surface Plasmon Resonance  
Our study started from the screening of a library of thirty-nine diterpenes (Fig. 
8) for their affinity towards Hsp70. The screening was performed by Surface 
Plasmon Resonance (SPR).  
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Figure 8. Structures of a library of plant compounds tested against Hsp70 by SPR screening. 
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Oridonin (Fig. 8) was used as positive control: previously published results 
indicated that this diterpene as ligand of Hsp70, exhibiting  a thermodinamic 
KD of 26 ± 1.2 nM and showing a covalent binding with Cys267 of Hsp70 
mediated by its α,β-unsaturated carbonyl group in position 15. 





all the analyzed compounds were selected based  
the importance of the carbonyl group in position 15 of oridonin.  Our achieved 
SPR sensorgrams inticated that six compounds (5, 9, 10, 11, 14 and 27) were 
demonstrated to bind the chaperon, with thermodinamic costants ranging from 
54 to 1000nM (Table 2). Compounds 9, 10, 11, 14 share a ∆16-17 (in R4) 





                                     a                                                      b 
 
 
Figure 9.  SPR Sensograms of  oridonin (positive control, a) of epoxysiderol (b). 
 
From our SPR results, the kaurane diterpene ent-7β-acetoxy-18-hydroxy-
15α,16α -epossikaurane, also known as epoxysiderol (compound 27), was the 
most active (Figure 10, sensorgram in figure 9b), showing higher affitiy for 
Hsp70 (KD= 54.1 ± 1.2 nM; kon (1/nMxs): 14.5 ± 1 ; koff [(1/s)x10
-3
]: 0.78 ± 
0.1). This compound shows an epoxide group between C15 and C16, positions 
where we found the α,β-unsaturated carbonyl group in oridonin. Therefore, 
and epoxide group in that position could be very impotant for the interaction 




      
Figure 10. Stucture of the ent-7β-acetoxy-18-hydroxy-15α,16α-epossikaurane (epoxysiderol). 
 
Interestingly,  also compound 28 presents an epoxide group, but the absence of 
binding activity for this compound could probably be explained by the 
different stereochemistry in comparison with the epoxide group of 27.      
 
 
Table 2. Thermodinamic constants measured by SPR of tested diterpenes on immobilized 
Hsp70. 
Compound KD (nM) ± SD Compound KD (nM) ± SD 
 Oridonin 26 ± 1.2  20 SPU 10/7 No binding 
1 Nervosanin B No binding  21 SPU 15/11 No binidng 
2 IRU 9/10 No binding  22 Siderotriol No binding 
3 IRU 5/5 No binding  23 Compound y No binding 
4 Ponidonin No binding  24 Compound e No binding 
5 Chetokauranic acid 400 ± 1.5  25 Diterpene D No binding 
6 Isofoliol No binding  26 EL 8/7 No binding 
7 PPU 3/21 No binding  27 Epoxysiderol 54 ± 1.2 
8 PPU 18/31 No binding  28 Compound  z No binding 
9 PPU 11/24 1180 ± 5  29 SPU 19/5 No binding 
10 PPU 7/44 100 ± 3  30 PPU 11/31 No binding 
11 PPU 3/10 1401 ± 7.5  31 Teuscorodin No binding 
12 PAF 8/40 No binding  32 Teuflidin No binding 
13 PAF 8/3 No binding  33 Teucrin A No binding 
14 PAF 6/18 615 ± 1.3  34 Teucrolivin B No binding 
15 PAF 7/7 No binding  35 Teuflavoside No binding 
16 PAF 9/11 No binding  36 PRE 1/11 No binding 
17 SPU 10/11 No binding  37 HFR 5/9 No binding 
18 SPU 11/7 No binding  38 SJ131 No binding 




Epoxysiderol (Fig. 10) is a  diterpene with ent-kauranic skeleton, isolated from 
plants of the genus Sideritis: S. sicula, S. euboea, S. roeseri, S. distans, S. 
dichotoma e S. syriaca.
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 The genus Sideritis (Lamiaceae) comprises more 
than 150 species widely distributed in temperate and tropical regions of the 
Northern Hemisphere. Most species are mainly found in the Mediterranean 
area, together with Canary and Madeira islands. This genus is characterized by 
a high number of hybridizations between species.
147
 The aerial parts 
of Sideritis species, known as ‗mountain tea‘, are used in Mediterranean 
countries folk medicine for gastrointestinal disorders such as stomach ache, 
indigestion, flautolence, to alleviate the symptoms of common colds, cough, 
rheumatism, and for tonic and diuretic effects.
148
 Anti-inflammatory, 
antioxidant, antiulcerogenic, antimicrobial, antiherpetical activities 
of Sideritis spp. extracts have also been reported, and some pure compounds 
isolated from this genus have shown antiproliferative, anti-HIV or antifeedant 
activities. Moreover, it is known that diterpenoids isolated from this genus are 
responsible of antifeedant, antimicrobial, and anti-inflammatory activities.
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Previous studies have shown the presence of mono-, sesqui-, di- and 
triterpenes, together with flavones, coumarins, phenylpropanoids and other 
aromatic derivatives in the Sideritis genus.
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 Epoxysiderol was isolated 
through chromatographic analyses and its structure was elucidated by 
spectroscopic methods (UV, NMR, MS). 
Once identified epoxysiderol as ligand of Hsp70 by SPR, the next steps of our 
study were aimed at: 
1) the validation of epoxysiderol as Hsp70 ligand; 
2) the evaluation of epoxysiderol  biological activity in cancer cells; 




3.2.2 MS-based studies on the epoxysiderol-Hsp70 interaction 
According to the several reactive aminoacids of Hsp70, the chemical structure 
of expxysiderol and the stability of Hsp70/epoxysiderol complex (KD= 54, 2 ± 
1.2 x10
-9 
M ), we investigated the characteristics of the interaction between the 
diterpene and the chaperone. To understand if the binding between 
epoxysiderol and Hsp70 was covalent or not, an LC-MS/MS-based peptide 
mapping analysis was implemented. To obtain an expedient peptide mapping 
for the coverege of Hsp70 sequence, we used Mascot Daemon (Matrix 
Science) software. Our analysis led to a  sequence coverage of 43% for the 
control (recombinant Hsp70 treated with only DMSO for 3h, fig.11a)  and  
47% for the treated (Hsp70 with epoxysiderol in ratio 1:100, fig. 11b). These 
results were further investigated by conducting a manual analysis of LC-
MS/MS spectra. The  analysis was performed using Paws software, and 
allowed us to obtain a final  sequence coverage of 84.5% for the control and 












                           a            b 
Figure 11. Mascot Research results.  a) sequence coverage calculated for  Hsp70 with only 




The manual analysis of the LC-MS/MS spectra also led us to investigate 
eventually modified peptides of Hsp70 involved in the interaction with 
epoxysiderol. In Figure 12 the HPLC spectra of control and  treated samples 
are shown: except very small variations in the retention time between the 
control spectrum (in black) and the treated  spectrum (in red), there was non 
significative difference between the two samples. 
                       
 
Figure 12. HPLC profiles of control and treated samples  chromatograms. In black:   control 
(Hsp70 with DMSO);  in red: Hsp70 treated with epoxysiderol (1:100 v/v).  
 
Analyzing MS/MS spectra, either way we could not find any m/z value that 
could match a covalent complex between epoxysiderol and Hsp70  (Fig. 13).  
 
Figure 13. MS profiles of control and treated samples. above: control (Hsp70 with DMSO);  




These results suggested the occurence of a non-covalent intraction 
between epoxysiderol and Hsp70.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
3.2.3 Cytotoxic activity of epoxysiderol 
The  cytotoxic activity of epoxysiderol was evaluated  by MTT assay on 
cancer cell lines such as HeLa (cervical carcinoma) and  Jurkat (T-cell 
leukemia), and also on nontumor human peripheral blood mononuclear cell 
line (PBMC). 
PBMC, Jurkat and HeLa cells were treated for 48h with DMSO (control) or  
epoxysiderol at different concentrations ranging from 5 µM up to 100 µM and 
the IC50 of the dose-effect curves was calculated (Table 3).    
Table 3. IC50 (μM) by MTT assay. 
Compound Jurkat HeLa PBMC 
Epoxysiderol 30 ± 1.5 µM 20 ± 0.9 µM >100 µM 
Data represent the mean ± SD of  3 different exeriments. 
 
The obtained results show that epoxysiderol plays a moderate antiproliferative 
activity against these tumor cell lines, being more effective on HeLa cells 
(IC50= 20 ± 0.9 µM) . On PBMC epoxysiderol did not show cytotoxic activity. 
Therefore, our next studies focused on this cell line, more susceptible to  
epoxysiderol.   
3.2.4 Validation study of epoxysiderol/Hsp70 interaction by DARTS 
In order to confirm Hsp70/epoxysiderol interaction in HeLa cells, we 
performed a cell-based assay by a Drug Affinity Responsive Target Stability 
(DARTS) approach, analyzing DARTS results by both WB and LC-MS/MS. 
HeLa cells (cervical carcinoma) were treated with epoxysiderol (15 µM) for 
2h; after the incubation, the cells underwent lysis with RIPA buffer, and the 
resulting protein extract was subjected to the limited enzymatic digestion, 
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carried out by adding  subtilisin (1:2000 w/w) for 20 minutes at 37°C. 
Subsequently, the partially digested proteins were fractionated by SDS-PAGE; 
each sample was divided in two aliquots, each loaded on a gel: in the first gel, 
the proteins were transferred into nitrocellulose membranes to perform a WB 
analysis. As shown in Figure 14, in the sample treated with subtilisin and 
epoxysiderol there was an enrichment of Hsp70 in comparison with the sample 
treated with only subtilisin: these data that epoxysiderol interacts with Hsp70 




                       
  
Figure 14.  Effect of treatment with epoxysiderol, 15 µM  for 2h  on  Hsp70 levels after 
treatment of HeLa cells with subtilisin (DARTS experiment).  GAPDH was used as loading 
control. The blots are representative of three different experiments with similar results. 
Numbers below  each lane represent the densitometric values. The blots are representative of 
at least three different experiments with similar results. 
 
The second gel, on the other hand, was treated with Fixing Solution for 30 
min, stained with Comassie Blue Colloidal overnight and washed with water. 
Afterwards, lanes of lysates treated with subtilisin  was cut into five pieces 
(Figure 15, in blue), digested with tripsin and analyzed by LC-MS/MS.                             
 




Figure 15. SDS Page carried on HeLa lysates. Each  sample treated with subtilisin  was split 
into five aliquots that underwent digestion with subtilisin, for 20 min at 37°C. Digestion was 
stopped by adding sample loading buffer and boiling immediately. Each sample was then 
loaded onto 10% SDS/PAGE gels and stained with Brilliant Blue G-Colloidal.  
 
In order to evaluate the relative abundance of Hsp70 in treated and control 
samples, we carried out further data analyses using the  Max Quant software. 
Each band of each lane underwent a digestion protocol with tripsin and then 
analyzed by LC-MS/MS. Each Raw file was then analyzed using Max Quant 
software, using a label-free quantification (LFQ) ―within groups‖  method 
(each band of the same lane was united). In Table 4, Hsp70 intensities of  
samples treated with only DMSO (control) and with epoxysiderol 15 µM for 
2h are shown.  
Achieved results were in agreement with DARTS results analyzed by WB, 
since the LFQ total intensity of treated samples is higher than the LFQ total 






Table 4. Max Quant software analysis. Each sample of control and treated lanes underwent a 
label free quantification analysis within groups.  






Heat shock 70 kDa 
protein 
70730 2986200 115855000 5.9*10
-7 
    38.8 
Data are representative of at least two different experiments with similar results.   
3.2.5 Western Blot of Hsp70, Hsp70 co-chaperones and client proteins 
Once demonstrating epoxysiderol/Hsp70 interaction by cell-free and cell-
based tecniques, and epoxysiderol cytotoxycity in Jurkat and HeLa cells, the 
following step of our study aimed to investigate more in detail the biological 
activity of epoxysiderol, focusing on the cellular pathways involving Hsp70. 
Firstly, we carried out WB in HeLa cells on Hsp70, in order to understand if 
epoxysiderol modulates Hsp70 levels. As shown in figure 16, Hsp70 levels 
decrease only after 48h at the highest concentrations of epoxysiderol (40 μM). 
These results are in agreement with MTT data.  About Hsp70 co-chaperones, 
also Hsp90 levels slightly decreased after 48h of incubation with epoxysiderol, 
whereas  BAG3 levels did not show any consistent modulation.   
We then focused on Hsp70 client proteins, partiularly those involved in cell 
proliferation, apoptosis and cell cycle phases progression. WB results showed 
a dose and time-dipendent reduction of NF-kB, p-Akt and p-ERK levels at 20 
µM and 40 µM after 24h and 48h; a reduction of AKT1, p38 (MAPK11), p-p38, 
JNK1 (MAPK8) and p-JNK1 levels after 48h of incubation with epoxysiderol 
(Fig.16). 
Based on these results, we can interestingly assert that epoxysiderol can 
modulate different cellular pathways involved in apoptosis, inflammation and 






Figure 16:  a) and b) Effect of epoxysiderol 15µM, 20 µM and 40 µM  on Hsp70, Hsp70 
client proteins and cochaperones levels in HeLa cells for 8h, 24h and 48h. Equal amounts 
(30µg) of total protein lysate were separated on SDS-PAGE and client proteins were 
visualized by Western Blot analysis. α-tubulin and GAPDH were used as loading controls. 
The blots are representative of three different experiments with similar results. Numbers 
below  each lane represent the densitometric values.  
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3.2.6 Evaluation of epoxysiderol biological activity in HeLa cells by flow 
cytometry and WB 
In order to understand if the reduction of HeLa cells treated with epoxysiderol 
is due to an effect of the diterpene on cell cycle or cell death (hypodiploidia), a 
flow cytometric analysis was implemented. HeLa cells were treatd with 
epoxysiderol (15µM, 25µM e 40µM) for 24h and 48h. Achieved results 
indicated that the diterpene tretment induces a subG0/G1 and a more evident  
G2/M cell cycle arrests after 48h of incubation (at 25µM and 40µM) (figure 
17).   
 
Figure 17. Effect of epoxysiderol on cell cycle progression. Flow cytometric evaluation of 
DNA content in HeLa cells treated with DMSO (control) or epoxysiderol (15µM, 25µM, 40 
µM) for 48h. On the Y axis: the percentages of cells in subG0/G1 (hypodiploidia) and in each 
cell cycle phase of epoxysiderol-treated cells subtracted for the corresponding percentages of 
control cells. Results are expressed as means ± SD of three experiment performed in duplicate 
(**p<0.005, *p<0.05). 
The involvement of epoxysiderol in G2/M cell cycle phase was validated by 
performing WB on cyclins Cdc2 and p-Cdc2, allowing us to discriminate the 
effect of epoxysiderol between the G2 phase and the M phase. Infact, Cdc2 or 
also called cyclin B, is necessary for the progression of the cells in and out of 
the M phase of the cell cycle. Therefore, HeLa cells were treated with DMSO 
(ctrl) or epoxysiderol (15µM, 25µM and 40µM for 48h). After lysis, proteins 
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underwent SDS-page, transfer onto nitrocellulose membranes, and WB 
analysis. Figure 18 shows the effect of epoxysiderol on G2/M phase changes 
depending on the concentrations used: at 15 µM we can observe an increase of 
p-Cdc2 levels compared to the control, thus suggesting an involvement in the 
M phase arrest of the cell cycle. On the contrary, at higher concentrations of 
epoxysiderol 25 µM and 40 µM of epoxysiderol, p-Cdc2 deacreases, causing a 
G2 phase arrest of the cell cycle.        
 
Figure 18.  Effect of epoxysiderol on cell cycle regulatory protein levels. Western Blot 
analysis of Cdc2 and pCdc2 (Thr161) levels in HeLa cells treated with DMSO (ctrl) or 
epoxysiderol (15µM, 25µM and 40µM) for 48h. For each immunoblot, band intensity was 
quantified by densitometry (numbers above each lane). GAPDH was included as a loading 
control. The blots are representative of at least two different experiments with similar results.  
 
In order to understand if the subG0/G1 cell cycle arrest was affecting apoptosis 
or necrosis events, an additional Flow Cytometry experiment, using  Annexin 
V, FITC Coniugate/PI protocol, was implemented. Achieved results showed 
HeLa cells in late (10.85%) and early (7.11%)  apoptosis after treatment of 
HeLa with epoxysiderol already at 15 µM for 48h (Fig. 19). No significative 
necrosis effect was observed.  
Therefore, the subG0/G1 cell cycle arrest caused by epoxysiderol was in 
agreement with WB results showed previously, according to the effect of 
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epoxysiderol on apoptosis pathways (reduction of pAkt, pERK2, JNK1 and  
p38). 
 In addition, PARP cleavage was observed by WB after treatment of HeLa 
cells with epoxysiderol 20µM and 40µM for 24h and 48h, confirming the 
involvement of epoxysiderol in apoptosis events mediated by PARP.  
 
 
Figure 19. Flow Cytometry experiment using Annexin V-FITC/PI protocol. a) HeLa cells 
treated with DMSO (control) for 48h. b) HeLa cells treated with epoxysiderol 25 µM for 48h. 
c) WB of HeLa cells treated with epoxysiderol 20 µM and 40 µM for 8h, 24h and 48h. For 
each immunoblot, band intensity was quantified by densitometry (numbers above each lane). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was included as a loading control and 
phenetyl  isothiocyanate (PEITC) as positive control. The blots are representative of at least 





3.2.7 Epoxysiderol effect on Hsp70 levels in subcellular compartments   
Hsp70 plays a crucial role in cancer progression. In particular, the Hsp70 
located in cytoplasm and specially on the plasma membrane are considered  
tumor markers. Indeed, plasma membrane Hsp70 is overexpressed in cancer 
cells than normal cells.
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In order to understand if epoxysiderol can modulate Hsp70 levels in different 
subcellular compartments in HeLa cells, a specific cell-based protocol was 
carried out. Our results were analized by WB. HeLa cells were incubated with 
oridonin 5µM and epoxysiderol 20µM for 4h at 37°C. After obtaining nucleus, 
cytosolic and plasma membrane extracts, each lysate was fractioned by SDS-
PAGE and the proteins were immunoblotted on a nitrocellulose membrane 
with antibodies specific for each cell compartment.  
As shown in figure 20, after 4h we can observe: 
- no modulation of Hsp70 levels into the nucleus; 
- reduction of Hsp70 levels into the cytoplasm (20% for oridonin 
and 40% for epoxysiderol); 
- reduction of Hsp70 levels on the plasma membrane (40% for 
oridonin and 50% for epoxysiderol);  
From these results, we could assert that epoxysiderol does not enter into the 
nucleus, whereas into the cytosol it does, modulating Hsp70 levels and its  






Figure 20. Effect of epoxysiderol on Hsp70 levels in nucleus, cytosol and plasma membrane. 
Western Blot analysis of Hsp70 levels in HeLa cells treated with DMSO (ctrl), oridonin 5µM 
and epoxysiderol 20 µM for 4h. For each immunoblot, band intensity was quantified by 
densitometry (numbers above each lane). α-tubulin was included as a loading control for 
cytosol and plasma membrane, Lamin A for the nucleus. Caveolin was used as control for 
plasma membrane extracts.  The blots are representative of at least two different experiments 
with similar results. 
3.2.8 Inhibition of Hsp70 ATPase activity mediated by epoxysiderol 
ATP hydrolysis and ADP/ATP exchange play a central role in Hsp70 
chaperone activity. Therefore, disruption of Hsp70-ATP interaction could lead 
to the inability of Hsp70 to perform its functions. Thus, the effect of 
epoxysiderol on ATP-dependent Hsp70 (using also its cochaperon Hsp40) 
biochemical functions was studied. To evaluate the effect of epoxysiderol 
binding on Hsp70, the ATPase activity was measured in the presence of 
different amounts of epoxysiderol (1 µM, 10 µM and 50 µM); oridonin was 
used as positive control.
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 Epoxysiderol was found to inhibit in a dose-
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dependent manner the Hsp70 ATPase activity (Fig. 21). 
 
Figure 21. Epoxysiderol effect on Hsp70 ATPase activity. Inhibition of the ATPase activity of 
Hsp70 treated with DMSO (control) or different concentrations of epoxysiderol, oridonin 
(positive control). Data are the means ± SD of two indipendent experiments performed in 
triplicate. *p<0.05, **p<0.005. 
 
























o r id o n in










3.2.9 Molecular docking experiment 
Presently, the knowledge of the structure and the dynamic of a small 
molecule/protein complex is crucial for drug discovery and for molecular bases 
studies of a pathological process. Thus, a characterization of epoxysiderol/Hsp70 
complex was performed by molecular docking calculations. Particularly, the 
analyses were performed using the protein structure recently crystallized by van 
Montfort et al. (PDB code: 5AQX).
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 In this study the authors reported the 
discovery of novel Hsp70 inhibitors following a fragment-based approach, 
disclosing the binding mode of these compounds able to directly interact in the 
ATP binding site of the protein. Due to the similar dimensions of epoxysiderol 
and the fragments co-crystallized with the protein, a computational investigation 
hypothesizing a similar binding mode for the diterpene was performed. For these 
reasons, molecular docking experiments were focused in the ATP binding site of 
the protein and performed using Glide software; afterwards, a careful analysis of 
the binding poses and of the set of interactions established with the protein 
counterpart was done. In details, as shown in Fig. 22, the most energetically 
favoured docking poses of epoxysiderol in the ATP binding site of Hsp70 showed 
a large hydrogen bond network with polar residues due to the presence of 
hydrogen bond acceptor (HBA) and donor (HBD) chemical functions on 
epoxysiderol, that strengthened the good placement of the compound on the NBD 






Figure 22. Epoxysiderol (represented in sticks and colored by atom types: C green, O red, polar H 
light grey) in docking with HSP70 ATP binding site (represented in ribbons, residues close to 
epoxysiderol are represented in sticks and colored by atom types: C grey, O red, N blue, polar H 
light grey). Hydrogen bond contacts are represented in dotted green lines. 
 
Specifically, hydrogen bonds were established with Tyr15, Lys56, Glu268, 
Lys271, Arg272, the latter identified as a key residue for developing/optimizing 
putative Hsp70 inhibitors.  
3.2.10 Conclusions 
Epoxysiderol was identified as main ligand of Hsp70 from the screening by SPR. 
This diterpene has been shown to have multiple biological activities; the 
antitumor effects of epoxysiderol have been related to its ability to interfere with 
several pathways, such as cell proliferation, cell cycle arrest and apoptosis. In the 





cells. Indeed, cell-free and cell-based assays were used as a tool to confirm the 
affinity of epoxysiderol towards Hsp70 and its ability to inhibit Hsp70 ATPase 
activity.Our biochemical cell-free studies demonstrated that Hsp70 showed a 
reduced ATPase activity after incubation with epoxysiderol. In addition, 
epoxysiderol affected the chaperone activity of Hsp70; this effect could be related 
to the ATPase activity inhibition, since Hsp70 client proteins strongly depend on 
its ATPase activity. Therefore, epoxysiderol may be considered as a new 
promising chemical scaffold to study the biology of this protein, and to develop 



























Materials and Methods 
 
 
3.3 Surface Plasmon Resonance (SPR) 
SPR analyses were carried out with a Biacore 3000 optical biosensor equipped 
with a research-grade CM5 sensor chip (GE Healthcare). Hsp70 1A (1.4 mg/ml, 
BPS Bioscience, 50287) 100µg ml
-1
 in 50 mM sodium acetate, pH 4.5., was 
immobilized on sensor chip surfaces at a flow rate of 5 µl ml
-1
 by using a standard 
amine-coupling protocol. Fourty compounds were dissolved in 100% DMSO to 
obtain 4mM solutions and diluited in 1:200 (v/v) in PBS (10mM NaH2PO4, 
137mM NaCl, 2.7mM KCl pH 7.4) containing variable amounts of DMSO, to 
achieve a final DMSO concentration of 0.1%. For each molecule a five point 
concentration series spanning 0.025-4µM was set up. SPR experiments were 
carried out at 25°C, with a 50 µl ml
-1
 flow rate. Association and dissociation times 
were set at 60s and 300s, respectively. Simple interactions were adequately fit to a 
single−site bimolecular interaction model to yield KD. BIAevaluation software 
(GE Healthcare) was used for sensorgrams elaboration. 
3.3.1 Drug Affinity Responsive Target Stability on HeLa cells 
Human HeLa cells (cervical cancer cells), were treated with epoxysiderol 30mM 
for 2h (final concentration 15 μM in 10ml) and DMSO 100% (5% in 10mL) , then 
lysed in RIPA buffer (10 mM Tris-Cl pH 7.6, 1 mM EDTA, 1% Triton X-100, 
0.1% sodium deoxycholate, 140 mM NaCl, 1 mM Phenylmethanesulfonyl 
fluoride) supplemented with protease and phosphatase inhibitors (P8340, Sigma-
Aldrich, St. Louis, MO, USA). Protein concentration was determined by Bredford 
assay (Bio-Rad, Hercules, CA, USA) using bovine albumin as standard. 
Subsequently, samples underwent proteolysis with Subtilisin (enzyme: lysate 





pH 6.8, 2% sodium dodecylsulfate, 10% glycerol, 0.01% blue bromophenol, 5% 
β-mercaptoethanol) was added to each sample to stop the reaction. Finally, the 
samples were incubated at 100 °C for 5 min and loaded in duplicate in two 10% 
mono dimensional SDS-PAGE gels, in order to perform at the same time MS and 
WB analyses. 
After performing SDS-Page, one gel was treated with Fixing solution 
(MEOH:CH3COOH:H2O 4:1:5) for 30min and then stained with Brilliant Blue G-
Colloidal (Sigma-Aldrich) overnight. After washing with water, each band of the 
gel line from 70 kDa to 45 kDa was cut and underwent a digestion protocol by 
tripsin (Promega, Milano, Italy): after washing with 0.1M AMBIC (Sigma 
Aldrich) and 100% ACN Romil (ROMIL Ltd, Cambridge, UK), the bands were 
reduced by DTT, alkylated using iodoacetamide, and treated with trypsin (0.013 
μg/μl) overnight at 37°C. The resulting fragments were extracted and analyzed by 
LC/MS/MS. 
3.3.2 Monodimensional electrophoresis SDS Page 
Polyacrylamide gel electrophoresis of SDS-denatured proteins was performed on 
10% acrylamide gel.  Composition of a 10% gel is shown below:  
 






3.3.3 LC/MS/MS Analysis 
The gel bands digested by tripsin, were subseqently analyzed by LC-MS/MS 
using a LTQ Orbitrap XL ESI-mass spectrometer (Thermo Fisher Scientific) 
equipped with a nano-ESI source, coupled with a nano-Aquity capillary UPLC 
(Waters): peptides separation was performed on a capillary BEH C18 column 
(0.075 mm × 100 mm, 1.7 µm, Waters) using aqueous 0.1% formic acid (A) and 
CH3CN containing 0.1% formic acid (B) as mobile phases. Peptides were eluted 
by means of a linear gradient from 10 % to 40 % of B in 45 min and a 300 nl•min-
1 flow rate. Peptide fragmentation was achieved using helium as collision gas and 
a collision cell energy of 30 eV. Mass spectra were acquired in a m/z range from 
400 to 1800, and MS/MS spectra in a m/z range from 25-2000. MS and MS/MS 
data were used by Mascot (Matrix Science) to interrogate the Swiss Prot non-
redundant protein database. Settings were as follows: mass accuracy window for 
parent ion, 10 ppm; mass accuracy window for fragment ions, 50 millimass units; 
fixed modification, carbamidomethylation of cysteines; variable modifications, 
oxidation of methionine. Proteins with scores > 65 and identified by at least 2 
significant sequences, were considered as reliable proteins. The quantitative 
analysis of the MS and MS/MS spectra  was performed using Max Quant 
software, obtaining LFQ intensities of control and treated samples.   
3.3.4 Hsp70 peptide mapping 
Hsp701A (0.5 μg/μl)  underwent incubation for 2h at 37°C with and without 
epoxysiderol (2mM) in ratio 100:1 ligand/protein. Subsequently, the samples were 
loaded in a 10% monodimensional SDSPage gel and digested with tripsin 
following the procedure described in paragraph 3.3.1. After digestion, the samples 





Peptide mapping was performed by Mascot Daemon (Matrix Science). The 
sequence coverage of the Hsp701A was further increased carring out a manual 
analysis of the MS spectra by using the Paws software. 
3.3.5 Cell culture and  treatment 
HeLa (cervical carcinoma) and Jurkat (T-cell leukemia) cell lines were purchased 
from the American Type Cell Culture (ATCC) (Rockville, MD, USA). The cells 
were maintained in DMEM (HeLa) or RPMI 1640 (Jurkat), supplemented with 
10% FBS, 100 mg/L streptomycin and penicillin 100 IU/mL at 37 °C in a 
humidified atmosphere of 5% CO2. To ensure logarithmic growth, cells were sub-
cultured every 2 days. Under given experimental conditions, untreated cells were 
able to double in number in less than 24 hr.  Stock solutions (50 mM) of purified 
compounds in DMSO were stored in the dark at 4 °C. Appropriate dilutions were 
prepared in culture medium immediately prior to use. In all experiments, the final 
concentration of  DMSO did not exceed 0.1% (v/v).  
3.3.6 Cell viability and cell cycle analyses 
Cells were seeded in 96-well plates and incubated for the established times in the 
absence (vehicle only) and in the presence of different concentrations of 
compounds and Etoposide as positive control. The day before treatments, cells 
were seeded at a cell density of 1×10
4 
cells/well. The number of viable cells was 
quantified by MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tet-razolium 
bromide]) assay. Absorption at 550 nm for each well was assessed using a 
microplate reader (LabSystems, Vienna, VA, USA). In some experiments cell 
viability was also checked by Trypan Blue (Lonza, USA) exclusion assay using a 
Bürker counting chamber. Half maximal inhibitory concentration (IC50) values 
were calculated from cell viability dose–response curves and defined as the 





Cell cycle was evaluated by propidium iodide (PI) staining of permeabilized cells, 
according to the available protocol, and flow cytometry (BD FACSCalibur flow 
cytometer, Becton Dickinson, San Jose, CA, USA). Data from 5000 events per 
sample were collected. The percentages of the elements in the hypodiploid region 
and in G0/G1, S and G2/M phases of the cell cycle were calculated using the 
CellQuest and MODFIT software, respectively.   
3.3.7 Determination of apoptosis 
HeLa cells (3x10
5
 cells/well) were incubated with DMSO (control) and 
epoxysiderol 25µM for 48h in a cell culture incubator. Cells were then processed 
for detection of apoptosis according to the protocol described in the Annexin V, 
FITC Apoptosis Detection Kit (Dojindo EU GmbH, Munich (Germany)). 
Following incubation, HeLa pellets were suspended in 100µL of Annexin V 
Binding Solution; subsequently, 5µL of Annexin V, FITC conjugate and 5µL of 
PI Solution were added in each sample and incubated for 15 min at room 
temperature with protection from light. After adding 400µL of Annexin V 
Binding Solution, samples were detected by Flow Cytometry (BD FACSCalibur 
flow cytometer, Becton Dickinson, San Jose, CA, USA) using Cell-Quest 
software.   
3.3.8 Western Blot analysis 
Cell whole lysates (HeLa) immunoblot analysis were prepared according to the 
standard protocol.  Protein concentration was determined by DC Protein Assay 
(Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as a standard. 
Proteins were fractionated on SDS-PAGE, transferred into nitrocellulose 
membranes, and immunoblotted with the appropriate primary antibody (1:1000). 
Signals were visualized with the appropriate horseradish peroxidase-conjugated 





GE Healthcare, NY, USA). Densitometry of bands was performed with ImageJ 
software. 
3.3.9 Cytosol and membrane extracts 
HeLa cells were washed twice with PBS, detached with trypsin-EDTA 1x in PBS 
(Euroclone), harvested in PBS and centrifuged for 5 minutes at 600 x g at 4°C. 
After that, the pellets were resuspended in 4 ml of lysis buffer (Tris HCl 20 mM, 
pH 7,4; sucrose 250 mM; DTT 1 mM; protease inhibitors, EDTA 1 mM in water), 
sonicated (5 seconds pulse - 9 seconds pause for 2 minutes, amplitude 42%) and 
then centrifuged at 4°C for 10 minutes, at 5000 x g. The obtained supernatants 
were ultra-centrifuged for 1 hour at 100000 x g at 4°C, until to get new 
supernatants that represent cytosol extracts. Each resulting pellet was resuspended 
in 4 ml of lysis buffer and ultra-centrifuged for 1 hour at 100000 x g at 4°C. The 
pellets were then resuspended in 250 µl of solubilization buffer (Tris HCl 20 mM, 
pH 7,4; DTT 1 mM; EDTA 1 mM; Triton X-100 1%, in water) and left overnight 
on orbital shaker at 4°C. After that, the solution was centrifuged for 30 minutes at 
50000 x g at 4°C: the supernatants represent membrane extracts. 
3.3.10 Nuclear extracts 
HeLa cells were washed twice with PBS, detached with trypsin-EDTA 1x in PBS 
(Euroclone), harvested in PBS and centrifuged for 5 minutes at 600 x g at 4°C. 
The pellets were resuspended in 500 µl of buffer A (Hepes pH 7.9 10 mM, EDTA 
pH 8.0 1 mM, KCl 60 mM, N-P40 0.2%, DTT 1 mM, PMSF 1 mM, protease 
inhibitors) and then left on ice for 10 minutes. After that, the samples were 
centrifuged at 660 x g for 5 minutes at 4°C and the surnatants  resuspended in 50 
µl of buffer C (Tris HCl pH 7.8 250 mM, KCl 60 mM, DTT 1 mM, PMSF 2 mM, 
glycerol 20% v/v in PBS) and centrifuged again at 9500 x g for 15 minutes at 4°C. 





mM, EDTA pH 8.0 1 mM, KCl 60 mM, DTT 1 mM, PMSF 1 mM, protease 
inhibitors) and centrifuged at 660 x g for 5 minutes at 4°C. The samples were then 
washed twice with 1 ml of buffer B, resuspended in 50 µl of buffer C and exposed 
to 3 cycles of freeze/thawing. Finally, the samples were centrifuged at 9500 x g 
for 15 minutes at 4°C: the pellets represent the nuclear extracts. 
3.3.11 ATPase activity Assay 
ATPase/GTPase Activity Assay Kit (MAK113-1KT) was from Sigma-Aldrich, 
performed by following the manufacturer‘s instructions. ATPase reactions were 
carried out for 3h at 37°C in Tris 40mM pH 7.4, NaCl 80mM, KCl 10mM, MgAc2 
8mM, EDTA 1mM, using Hsp70 1A (1.4 mg/ml, BPS Bioscience, 50287, final 
concentration of 1µM in 20µL), Hsp40 (2,3 mg/ml, BPS-Bioscience, 90303)  and 
different concentrations of epoxysiderol 10µM, 50 µM and 100µM in final 
volume 20µL). Oridonin was used as positive control. Subsequently, ATP 4mM 
was supplemented  to each mixing solution for 40min at room temperature, before 
adding 80µL of malachite green reagent. ADP generation was measured after 
30min with a Thermofisher UV Spectrophotometer (540 nm excitation and 620nm 
emission). Absorbance intensity values measured for Hsp70 without any testing 
compound was assumed as 100% of enzime activity. The background reaction 
rate was measured in a reaction lacking enzyme or substrate and subtracted from 
the experimental rates. 
3.3.12 Reagents and Antibodies 
Fetal bovine serum (FBS) was from GIBCO (Life Technologies, Grand 
Island, NY, USA). The anti-HSP90α (mouse monoclonal SPA-835) was obtained 
from Stress-gen Bio-reagents Corporation (Victoria, Canada). Anti-BAG3 (rabbit 
polyclonal) was obtained from Biouniversa s.r.l (Montoro, AV, Italy). The 





polyclonal sc-571), anti-pJNK (mouse monoclonal sc-6254), anti-NFkB (mouse 
monoclonal sc-7386), anti-p-p38 (rabbit polyclonal sc-17852 ), anti p-38 (mouse 
monoclonal sc-7972), anti-pAkt (rabbit polyclonal sc-7935-R), anti-Akt (rabbit 
polyclonal), anti-Cdc2 (mouse monoclonal, sc-8395) and anti-phospho (Thr161)-
Cdc2 p34 (rabbit polyclonal, sc-101654), anti-Erk1/2 (mouse monoclonal sc-
1647), anti-pErk (mouse monoclonal sc-7383),  anti-α-Tubilin (mouse 
monoclonal sc-32293), anti-GAPDH (rabbit polyclonal), anti-caveolin (rabbit 
polyclonal  sc-894) were obtained from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Inc., Delaware, CA, USA); anti-lamin A (L1293 rabbit 
polyclonal) was purchased from Sigma-Aldrich (USA); anti-PARP (#9542 rabbit 
polyclonal) was purchased from Cell-Signaling (USA);   appropriate peroxidase-
conjugated secondary antibodies were from Jackson Immuno Research 
(Baltimore, PA, USA).    
3.3.13 Molecular Docking Studies     
The 3D chemical structure of epoxysiderol was built using Maestro v. 10.7 
(Schrödinger Suite). Afterwards, the generated structure was prepared using 
LigPrep software (Schrodinger Suite), and the structures were minimized using 
OPLS 2005 force field. Protein 3D model was prepared using the Schrödinger 
Protein Preparation Wizard, starting from the Hsp70 X-ray structure co-
complexed with the inhibitor KC7 ((1R,2S,3R,5R)-3-((5-(benzyloxy)quinazolin-4-
yl)amino)-5-(hydroxymethyl) cyclopentane-1,2-diol) (PDB code: 5AQX).  Water 
molecules were removed, all hydrogen atoms were added, and bond orders were 
assigned. Docking calculations were performed after removal of the co-
complexed compound KC7. Molecular docking experiments were performed 
using Glide software, using the Extra Precision scoring/sampling mode (XP), 





3.3.14 Statistical analysis 
Data reported are the mean values ± SD from at least three experiments, 
performed in duplicate, showing similar results. Differences between treatment 
groups were analyzed by Student's t-test.  Differences were considered significant 



























































































4.1 Heat Shock Protein 90: isoforms and localizations 
Heat shock protein 90 (Hsp90) is one of the most abundant chaperones  among  
the heat-related proteins. The "90" comes from its molecular  weight, which is 
roughly 90 kDa. Heat shock protein 90 assists other proteins to their correct 
folding. It also stabilizes a number of proteins required for tumor growth (such as 
AKT,  ERK, EGFR, Survivin and others), so Hsp90 modulators are investigated 
as anti-cancer drugs. 
Hsp90 is highly conserved and expressed in a variety of different organisms, it is 
found in bateria and all branches of eukaria, but it is absent in archea. 
151
 Whereas 
cytoplasmic Hsp90 is essential for viability under all conditions in eukariotes, the 
bacterial homologue HtpG (high-temperature protein G, with 40% sequence 
identity and 55% similarity to the human protein) is dispensable under non-heat 
stress conditions. Several eukaryotes possess specialized mitochondrial (TRAP1) 
and endoplasmic reticulum (GRP94/GP96/endoplasmin) isoforms. 
151
  
 Yeast Hsp90 is 60% identical to human Hsp90α. In mammalian  cells, there are 
two or more genes encoding cytosolic Hsp90 homologues, with the human 
Hsp90α showing 85% sequence identity to Hsp90β.
152, 153 
In table 1 the different 












Table 1. The five functional human genes encoding Hsp90 protein isoforms  






HSP90AA1 Hsp90-α1 cytosolic 





















4.1.1 Hsp90  structure  
Hsp90 consists of four structural domains  (Fig. 1):
154
  
 a highly conserved N-terminal  domain (NTD) of ~25 kDa, with an adenosine 
triphosphate (ATP)-binding and hydrolyzing pocket, responsible for the 
ATPase activity of Hsp90; 
 a "charged linker" region, that connects the N-terminus with the middle 
domain (MD); 
 a middle domain (MD, divided in M1 and M2 domains) of ~40 kDa,  involved 
in co-chaperones and client proteins recognition/binding; 
 a C-terminal  domain (CTD) of ~12 kDa, able to modulate Hsp90 
dimerization. In addition, it contains the tetraricopeptide repeat-binding 
(TRP) motif, as well as its co-chaperones such as Hsp organizing protein 
(Hop). The TRP motif allows the binding to Hsp90 and the regulation of its 






Figure 1. Domains and functional regions of Hsp90. The structure of Grp94 is shown. A) 
Schematic organization. B) Cartoon representation of the Grp94 dimer. C) surface representation 
of the Grp94 monomer. Adopted from: Maharaj KA et al. 2016;  PLoS ONE.   
 
The NTD shows homology  not only among members of the Hsp90 chaperone 
family but also to members of the ATPase/kinase GHKL (Gyrase , Hsp90, 
Histidine Kinase, MutL) superfamily.
 
This domain is responsible of ATP 
hydrolysis,  required for the correct protein folding mediated by Hsp90.
155
 
The MD is divided into three regions: 
 a 3-layer α-β-α sandwich; 
 a 3-turn α-helix and irregular loops; 





The MD is also involved in client protein binding. For example, proteins known 




 The CTD possesses the dimerization region. The dimer formation is independent 
of nucleotide binding or client proteins or co-chaperones  interactions. On the 
other hand, the dimerization of the N-terminal domains is dependent on binding. 
Residues in the MD and CTD are involved in interactions with the majority of 
clients, however residues in the NTD also participate in binding some specific 
clients.
157
 Co-factors such as the immunophilins  FKB (p51) and FKB (p52) , the 
stress induced phosphoprotein 1  (Sti1/Hop), and many more proteins interact 
with the TRP motif recognition site (MEEVD pentapeptide).
158
 
4.1.2  Hsp90 ATPase activity and ATP binding site 
As shown in Figure 2, a correct peptide folding includes Hsp40, Hsp70, HIP, 
HOP, Hsp90, immunophilin and p23 (Prostaglandin E synthase 3)  proteins.
159
 
Just after translation, the unfolded peptide binds to Hsp40 and Hsp70 (top, left).  
Subsequently, HOP (composed of TPR domains) delivers it to Hsp90. HOP 
mediates interaction between Hsp70 and Hsp90 through their C-terminal domains. 
This transfer takes place only if ADP is bound to Hsp90. The exchange of ADP 
to ATP inside N-terminal pocket induces dissociation of Hsp70 and its co-
chaperones from the complex that associates then with p23 (via N-terminal side of 
Hsp90 dimer) which prevents ATP hydrolysis, and immunophilins, which 
replaces HOP (right). The binding of ATP triggers the dimerization of the N-
terminal domains and enables the client protein activation/binding. Hsp90-bound 
ATP is then hydrolyzed, and the energy released by ATP hydrolysis enables the 
client protein folding, leading to the dissociation of the complex Hsp90-peptide. 





orientation in which the N-terminal domains dimerize to a wide, open V-shaped 




Figure 2.  Hsp90-dependent ATP hydrolysis cycle of client proteins activation. 
 
Amino acids that are directly involved in the interaction with ATP are Leu34, 
Asn37, Asp79, Asn92, Lys98, Gly121, and Phe124. In addition, Mg
2+
 and several 
water molecules form briding electrostatic and hydrogen bonding interactions, 




If  the chaperone binds geldanamycin, a known Hsp90 inhibitor which mimics 
ADP binding, p23 and HOP dissociate and CHIP, an E3 ubiquitin ligase, is 
attached to the complex and the protein is  degraded through the proteasome-
mediateted pathway. Immunophilins are responsible for transportation of Hsp90-





the microtubule-associated proteins are involved in this process). Therefore, a 
translocation of hormones, p53 and probably other Hsp90 substrate proteins 
within cytoplasm is fast and tightly controlled.
159
 
Hsp90 ATP-binding site is located in a pocket on the helical face of the N-
domain. In the crystal structure the bound nucleotide interacts with hydrophobic 
residues of the pocket (Fig 3A and B), and with solvent molecules that mediate 
key polar interactions. Particularly, the ATP adenine base penetrates in the pocket 
with one face against hydrophobic side chains and makes one single hydrogen 
bond to the side chain of ASP79. Water molecules mediate other polar 
interactions, specially with the ribose sugar while the α and β phosphates of the 
ATP are coupled to the protein via an octahedrally coordinated Mg
2+
 ion (Fig 
3C).
161
 Microbial antibiotics such as geldanamycin and radicicol are both able to 
bind Hsp90 in the same pocket of ATP (Fig. 3E and F). They possess anti-tumor 
activity and ability to interfere with protein kinase pathways,
162
 although their 
mechanism of action is not fully understood. Nevertheless, they can be identified 
as inhibitors of ATP-binding to Hsp90.
161














Figure 3. ATP-binding site of Hsp90. A) ATP/ADP binds into a pocket formed in the helical face 
of the N-terminal domain. B) Molecular surface of Hsp90 N-domain colored according to 
electrostatic potential blue:+ve, red:- ve. The adenine base is buried in the binding pocket with the 
phosphates exposed to solvent. C) Close up of the water-filled nucleotide-binding pocket. Polar 
interactions made by the bound ADP are shown as dashed lines. D) The adenine base makes only a 
single direct hydrogen bond with the protein, via the side chain of Asp 79. E) The natural product 





by Hsp90. F) The natural product radicicol binds to the nucleotide-binding pocket and is a 
competitive inhibitor of ATP binding by Hsp90. Adopted from:  Pearl LH. 2016; Biopolymers.  
4.1.3 Hsp90 client proteins  
The Hsp90s are a family of molecular chaperones that function in the cellular 
stabilization, regulation, and activation of a variety of client proteins, such as 
oncogenic protein kinases and  nuclear steroid hormone receptors, in order to 
obtain their active conformation.  Many of these client proteins are involved in 
critical cellular functions that promote cell growth, proliferation and cell survival 
which are also important to maintain the cancer phenotype.
163
  
Hsp90 is also implicated in the assembly of RNA polymerases, PI3-kinase-like 
kinases such as mTOR and SMG1, snoRNPs8 and NLR innate immunity 
receptors.
164
 Recent high-throughput screening experiments have also identified 
E3 ubiquitin ligase subunits interacting with Hsp90, but whether these are actually 
dependent as a class on Hsp90 for their function remains to be shown.
165
 The 
ability of Hsp90 to engage with its client proteins (Fig. 4) is mediated by co-
chaperones that act as adaptors and modulate the specificity and selectivity for 
client proteins. For the best of our knowledge, the simplest of these adaptor co-
chaperones is Cdc37, which mediates recruitment of members of the eukaryotic 







Figure 4. Hsp90 and its clients. Hsp90 engages with a range of ‗client‘ protein classes (outer 
circle) via its interaction with various co-chaperone proteins or complexes (inner circle), that act as 
adaptors, simultaneously able to interact with the specific client and the central chaperone itself. 
Adopted from:  Pearl LH. 2016; Biopolymers. 
 
Steroid hormone receptors (estrogen and glucocorticoid receptors) are coupled to 
Hsp90 via the TPR-domain protein Hop.
166
 Other TPR-domain co-chaperones 
such as AIP and FKB(p38) have been implicated in recruitment of such diverse 
proteins as aryl hydrocarbon receptor and hepatitis C NS5A to the Hsp90 system, 
but the mechanistic details of these process are not yet well understood.
167
 The 
most complex Hsp90 co-chaperone system described to date, is the R2TP 
complex,  a complex of four different proteins recruited to Hsp90 via the TPR-
domain. R2TP couples Hsp90 to stabilization and assembly of snoRNPs, RNA 




4.1.4 Functions of Hsp90 in cancer 
Hsp90 is overexpressed in cancer cells and several of its client proteins are 





and others) that represent nodal points in multiple oncogenic signaling 
pathways.
169
 In addition, oncoproteins are often mutated and/or overexpressed in 
cancer cells, and maintenance of their malignancy requires higher Hsp90 activity 
than normal cells. Hsp90 client oncoproteins are also involved in other hallmark 
process of cancer, including induction of angiogenesis, mediation of apoptosis, 
and promotion of tissue invasion and metastasis. Hsp90 influences angiogenesis 
by chaperoning hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial 
growth factor receptor (VEGFR) in addition to governing nitric oxide synthase 
upregulation. Hsp90 chaperones client proteins are also apoptotic mediators, 
including Bcl-2, Apaf-1, the serine-threonine protein kinase AKT/PKB and 
Survivin. Moreover, Hsp90 may promote tissue invasion and metastasis through 
MMP-2 activation, digesting extracellular matrix proteins. Other client proteins of 
Hsp90 that play a role in cell signaling processes include FAK (integrin pathway), 
IL6R (JAK/STAT3 pathway) and IκB kinases (NFκB pathway).
170
 Based on this 
knowledge, the  inhibition of the Hsp90 protein folding machinery can lead to the 
simultaneous disruption of multiple cellular pathways that are crucial for the 
growth and survival of cancer cells, which represents a multifaceted approach to 
tumor treatment. 
 
4.1.6 Hsp90 inhibitors: therapeutic targeting of Hsp90 ATPase activity  
The involvement of Hsp90 in the stabilization of many highly oncogenic protein 
kinase clients and the revelation of Hsp90 as an ATP-dependent protein with a 
‗druggable‘ nucleotide-binding site in its N-terminal domain, prompted a 
remarkable level of interest in Hsp90 as a therapeutic target in cancer. Progress 
was greatly assisted by the availability of natural compounds such as 
geldanamycin and radicicol.
162
 The approach was confirmed in early studies using 





downregulation of key oncogenic client proteins such as ERBB2, CRAF, and 
AKT, and loss of signaling through critical cancer-driving signaling pathways in 
cell lines and in patients.
171
 Presently, there are more than a dozen Hsp90 ATP-
competitive inhibitors in clinical trials at various stages, with promising activity 
against a range of tumors, such as radicicol (a macrocyclic antifungal antibiotic), 
geldanamycin (a benzquinoid ansamycin antibiotic) and other derivatives (Fig. 5). 
 
Figure 5. Hsp90 inhibitors. Structures of radicicol, geldanamycin and of a number of synthetic or 
semisynthetic ATP-competitive Hsp90 inhibitors currently in clinical development. 
 
The multiple functions played by the molecular chaperone Hsp90, particularly in 
response to different type of stress, make this protein a promising target for 
several therapeutic approaches.
172
 The modulation of Hsp90 has indeed been 
proposed as an efficient strategy to face multiple cancer types.
173
 Many plant 
metabolites, belonging to different classes, have been shown to efficiently interact 
with Hsp90, inhibiting its activity in cancer cell and exerting a significant 









Results and discussion 
 
4.2 Screening of fusicoccane and abietane diterpenes by SPR   
A SPR technology by Biacore was implemented to screen a collection of twenty-
eight diterpenes with proven pharmacological activities to identify Hsp90 
interactors. Particularly, sixteen diterpene fusicoccane skeletons from Hypoestes 
forsskaolii (Acanthaceae) and twelve abietanes from  Zhumeria majdae 
(Lamiaceae) and different Salvia spp. (Lamiaceae) were tested in our studies (Fig. 
6).  
 





The affinity towards the molecular chaperone Hsp90 was assayed by SPR for the 
isolated compounds  (Table 2). 
Table 2. Thermodynamic Constants Measured by Surface Plasmon Resonance for the 
Interaction between tested compounds and immobilized Hsp90 α  
Compound KD (nM)
a ± SD 
1 401 ± 4 
2 20.5 ± 1.2 
3 130 ± 1 
4 217 ± 17 
5 45 ± 4 
6 15.3 ± 0.2 
7 no binding 
8 no binding 
9 no binding 
10 120 ± 1 
11 28 ± 3 
12 1000 ± 25 
13 1739 ± 75 
14 no binding 
15 no binding 
16 no binding 
17 161 ± 2 
18 no binding 
19 no binding 
20 2.97 ± 0.5 
21 no binding 
22 no binding 
23 no binding 





25 no binding 
26 no binding 
27 no binding 
28 no binding 
radicicol 1.2 ± 0.1 
17-AAG 388 ± 89 
a
Results were given mean ± standard deviation. 
17-AAG and radicicol were used as positive controls 
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 SPR assay led us to 
obtain the thermodynamic and kinetic parameters of fusicoccanes/Hsp90 α 
complex formation. Nine (2-6, 10-11, 17 and 20), out of the twenty tested 
compounds interacted with the protein (Table 2): among them, compounds 2, 6, 
11 and 20 showed higher affinity towards the chaperon, as inferred by the 
measured KD values falling in the 3-30 nM range.  
Due to the limited number of tested compounds and their structure variability, 
structure activity relationship study could not be attempted. Anyway, our data 
suggested that the interaction between fusicoccanes/abietanes and Hsp90  could 
involve multiple sites on their backbone. 
4.2.1 Antiproliferative activity of fusicoccanes and abietanes tested by MTT 
on Jurkat, HeLa and MCF7 cell lines  
On the basis of the ability of these compounds to bind Hsp90α, we evaluated the 
potential antiproliferative or cytotoxic activity of the diterpenes on human HeLa 
(epithelial carcinoma), Jurkat (human T-cell lymphoma) and MCF7 (breast 
cancer) cell lines. The cells were incubated for 48h with increasing concentration 
of fusicoccanes and abietanes (10-150 µM) and cell viability was determined by 
MTT assay.
175
 Among tested fusicoccanes, 1, 2, 4, 9, 14-16,  were inactive, while 
3 showed low activity on Jurkat cells, and 8 and 10 were not effective towards 





Compound 6 demonstrated an interesting antiproliferative activity in HeLa cells, 
showing an IC50 value of 18 ± 1 µM (Table 3). 
Table 3. IC50 (μM) Values of tested compounds against two cancer cell lines
a 
compound Jurkatb HeLac 
1 >100 >100 
2 66 ± 3 >100 
3 44 ± 2 >100 
4 70 ± 3 >100 
5 45 ± 1 38 ± 1 
6 45 ± 3 18 ± 1 
7 >100 >100 
8 >100 50 ± 4 
9 >100 >100 
10 >100 50 ± 2 
11 49 ± 2 48 ± 2 
12 65 ± 3 35 ± 2 
13 47 ± 2 50 ± 3 
14 >100 >100 
15 >100 >100 
16 >100 >100 
etoposide 2.5 ± 0.4 4.0 ± 0.83 
a






Compounds 17-19 and 21-28 were not effective towards HeLa but showed 
moderate activity on MCF7. Compound 20 was found as the most active on 
MCF7 cells, showing an IC50 of 20 ± 2 µM (Table 4).  therefore, we decided to 
focus of the fusicoccane 18-hydroxyhypoestenone (6) and  the abietan lanugon Q 





activity on the nontumor human peripheral blood mononuclear cell line (PBMC) 
up to 100 µM. 
 











4.2.2 Evaluation of the biological activity of the selected diterpenes  by flow 
cytometry and WB 
The mechanism of action of cancer cell viability inhibition exerted by 6 was 
investigated incubating HeLa cells for 48h with concentrations close to the IC50 
values of 6 (10 and 20 µM) and analyzed by flow cytometry. The treatment 
caused a G2/M cell cycle arrest (Fig. 7A). Hsp90 α  inhibition could induce G2/M 
arrest by affecting, directly or indirectly, the levels and the phosphorilation state 
compound MCF7b HeLac 
17 >50 >50 
18 45 ± 2 >50 
19 44 ± 1 91 ± 3 
20 20 ± 2 >50 
21 >50 >50 
22 >50 >50 
23 >100 >100 
24 >50 >50 
25 >100 >100 
26 >50 >100 
27 >100 >50 
28 >50 >50 





of several cyclins and cyclin-dependent kinases (CDKs).
176, 177 
On this basis, the 
cell cycle arrest induced by 6 was studied evaluating the expression of these 
proteins. WB Results (Fig. 7B) indicated that the cell cycle arrest in G2/M phase 
observed for the HeLa cells was accompanied by a significant decrease in the 
level of phosphorylated-Thr161 Cdc2/p34 protein.  
 
Figure 7. Effect of 6 on cell cycle progression and on cell cycle regulatory protein levels. A) Flow 
cytometric evaluation of DNA content in HeLa cells treated with DMSO (control) or 6 (10 and 20 
µM) for 48 h. On the Y axis: the percentages of cells in subG0G1 (hypodiploidia) and in each cell 
cycle phase of 6-treated cells subtracted for the corresponding percentages of control cells. Results 
are expressed as means ± SD of three experiment performed in duplicate (**p<0.005, *p<0.05). B) 
Western Blot analysis of Cdc2 and pCdc2 (Thr161) levels in HeLa cells treated with DMSO (ctrl) 
or 6 (10 and 20 µM) for 48 h. For each immunoblot, band intensity was quantified by densitometry 
(numbers above each lane). GAPDH was included as a loading control. The blots are 
representative of at least two different experiments with similar results. 
 
Subsequently, compound 6 (10 and 20 µM) was tested for its effect on some 
Hsp90 α client proteins level in the HeLa cells (Fig. 8); 6 was able to induce a 
strong depletion of p-Akt and p-ERK1 proteins (Fig. 8B), while the Hsp70 level 






Figure 8. Effect of 6 on Hsp90α client proteins levels in HeLa cells after treatment with 6 (10 and 
20 µM) for 48h. Equal amounts (30 µg) of total protein lysate were separated on SDS-PAGE and 
client proteins were visualized by Western Blot analysis. α-tubulin and GAPDH were used as 
loading controls. The blots are representative of three different experiments with similar results. 
Numbers above each lane represent the densitometric values.  
Also compound 20 was investigated for its intracellular activity on Hsp90α client 
proteins by WB in MCF7 cells (Fig.9). After treatment of MCF7 with 20 (18 µM) 
for 48h, we observed: 
- a moderate reduction of Hsp90 levels; 
- strong decrease of p-Akt, p-ERK1 and cyclin A levels. 






Figure 9. Effect of lanugon Q (20) on Hsp90α client proteins levels in HeLa cells after treatment 
with 20 (18 µM) for 48 h. Equal amounts (30 µg) of total protein lysate were separated on SDS-
PAGE and client proteins were visualized by Western Blot analysis. GAPDH was used as loading 
control. The blots are representative of three different experiments with similar results. Numbers 
above each lane represent the densitometric values.  
 
From these these results we can assert that both 6 and 20 can, directly or 
indirectly, determine a decrease of some of Hsp90α client proteins involved in 
anti-apoptotic and  proliferative pathways in two different cell lines such as HeLa 
and MCF7. 
4.2.3 Effect of 6 and 20 on Hsp90α ATPase activity  
To investigate the possible effects of compound 6 and 20 on Hsp90α bioactivity, 
its ATPase enzymatic activity was investigated. Radicicol and hypoestenonol B 
(16), showing no affinity towards the chaperone in the SPR studies, were selected 
as positive and negative control, respectively. ATPase activity of Hsp90α was 
affected by 6 at 5 and 10 µM (Fig. 10), showing an inhibition almost comparable 
to that of radicicol. On the other hand, compound 20 did not show any ATPase 






                             
Figure 
10. Compound 6 effect on Hsp90 α ATPase activity. Inhibition of the ATPase activity of Hsp90 α 
treated with DMSO (control) or different concentrations of 6, radicicol (positive control), and 16 
(negative control). Data are the means ± SD of two independent experiments performed in 
triplicate. *p < 0.05, **p < 0.005. 
4.2.4 Study of the interaction Hsp90α /6 by molecular docking 
 To rationalize the Hsp90α ATPase activity inhibition and the biological effects of 
the selected fusicoccane diterpene in terms of interaction with Hsp90 α, molecular 
docking studies between 6 and Hsp90 α protein were performed. In more details, 
the ATP-bound active state of Hsp82, a yeast Hsp90 α homologue (PDB code: 
2CG9), was used as a model receptor and its sequence alignment with the human 
protein, reported by Lee et al.,
178
 was used as reference during the comparative 
experimental–computational analysis. We have used the Induced Fit docking 
protocol,
179
 to account accurately for both  ligand and receptor flexibility due to 
the high plasticity of the Hsp90 during its mechanism of action. 
Starting from biological evaluation reported above, we have considered the region 





area of pharmacologic interest. From the structural point of view, 6 interacts with 
chaperone structure by two hydrogen bonds between the CO group at C-5 and the 
OH group at C-18 with Leu676chainA and Leu670chainB respectively, and by 
hydrophobic interactions of fusicoccane diterpene skeleton with the side chains of 
chains A and B (Fig. 11). Therefore, the computational analysis of interaction 
pattern of Hsp90/6 complex suggests a C-terminal inhibition mode.  
       
Figure 11. Three dimensional models of 6 (violet sticks) with the C-terminal domain of the 
HSP82 yeast analogue of Hsp90α (chain A is depicted in green and chain B in cyan).  
4.2.5 Conclusions  
In the present study we identified 18-hydroxyhypoestenone (6) and lqnugon Q 
(20) as novel modulators of Hsp90 by SPR. Moreover, from MTT, flow 
cytometry and WB experiments they showed cytotoxicity, cell cycle arrest and 
reduction of client proteins involved in cell proliferation and cancer progression 





dependent ATPase activity inhibtion of the chaperone. In addition, molecular 
docking studies showed a possible interaction between 6 and the C-termnal 
domain of Hsp90. This domain plays a crucial role forHsp90/co-chaperones 
interctions; therefore, a possible interaction with this domain could lead to the 
consequent inhibition of several protein client folding.  
In conclusion, 18-hydroxyhypoestenone and  lanugon Q  may be considered as a 
new chemical hit compounds of this protein, and a starting point to obtain  new 




























Materials and methods 
 
4.3 Reagents and Antibodies 
 Fetal bovine serum (FBS) was from GIBCO (Life Technologies, Grand Island, 
NY, USA). Hsp90 α was purchased from Tebu Bio Italy (Magenta, Milan, Italy) 
and bovine serum albumin (BSA) was from Sigma-Aldrich (Saint Louis, MO, 
USA). The antibody anti-Hsp90α (mouse monoclonal SPA-835) was obtained 
from Stress-gen Bio-reagents Corporation (Victoria, Canada). The antibodies anti-
Hsp70 (mouse monoclonal sc-32239), anti-cyclin A (rabbit polyclonal sc-596-G), 
anti-pAkt (rabbit polyclonal sc-7935-R), anti-Akt (rabbit polyclonal), anti-Cdc2 
(mouse monoclonal, sc-8395) and anti-phospho (Thr161)-Cdc2 p34 (rabbit 
polyclonal, sc-101654), anti-Erk1/2 (mouse monoclonal sc-1647), anti-pErk 
(mouse monoclonal sc-7383), anti-α-tubilin (mouse monoclonal sc-32293), anti-
GAPDH (rabbit polyclonal), were obtained from Santa Cruz Biotechnology 
(Santa Cruz Biotechnology, Inc., Delaware, CA, USA); anti-EGFR (rabbit 
polyclonal) were obtained from Cell Signaling Technologies, Danvers, USA; 
appropriate peroxidase-conjugated secondary antibodies were from Jackson 
Immuno Research (Baltimore, PA, USA). 
4.3.1 Surface Plasmon Resonance Analyses 
 SPR analyses were performed using a Biacore 3000 optical biosensor, equipped 
with research-grade CM5 sensor chips (GE Healthcare, Milano, Italy). 
Recombinant human Hsp90 α (SPP-776, Stress-gen Bio-reagents Corporation, 
Victoria, Canada) was dissolved at 100 µg/mL in CH3COONa 50 mM, pH 5.0) 
and immobilized on a CM5 sensor chip surface using standard amine-coupling 
protocols and flow rate of 5 µL/min, to obtain an optical density of 15 kRU. All 





dissolved in 100% DMSO to obtain 4 mM solutions, and diluted 1:200 (v/v) in 
PBS (10 mM NaH2PO4, 150 mM NaCl, pH 7.4) to a final DMSO concentration of 
0.1%. For each molecule, a five-points concentration series were set up, spanning 
25 nM–50 nM–250 nM–1 µM–4 µM, and for each sample the complete binding 
study was carried out using triplicate aliquots. SPR experiments were performed 
at 25 °C, using a flow rate of 50 µL/min, with 60 s monitoring of association and 
300 s monitoring of dissociation. Changes in mass, due to the binding response, 
were recorded as resonance units (RU). To obtain the dissociation constant (KD), 
these responses were fit to a 1:1 Langmuir binding model by nonlinear regression, 
using the BiaEvaluation sofware program provided by GE Healthcare. Simple 
interactions were suitably fitted to a single-site bimolecular interaction model (A 
+ B = AB), yielding a single KD.  
4.3.2 ATP hydrolysis inhibition 
 The assay was performed using the ATPase/GTPase Activity Assay Kit 
(MAK113-1KT) from Sigma-Aldrich, and following the manufacturer‘s 
instructions. ATPase hydrolysis was carried out for 3 h at 37 °C in Tris 40 mM 
pH 7.4, NaCl 80 mM, KCl 10 mM, MgAc2 8 mM, EDTA 1 mM, using Hsp90α 
from Tebu Bio Italy (Magenta, Milan, Italy) 2.2 mg/mL (final concentration: 1 
µM in 20 µL) and different concentrations of 6 (1 µM, 5 µM and 10 µM in 20 µL, 
final volume). Subsequently, ATP 4 mM was supplemented to each mixing 
solution for 40 min at room temperature, before adding 80 µL of malachite green 
reagent. ADP generation was measured after 30 min of incubation by a 
Thermofisher UV Spectrophotometer (540 nm excitation and 620 nm emission). 
Absorbance intensity value measured in the absence of compound 6 was assumed 
as 100% of Hsp90 α activity. The background reaction rate was measured in a 





4.3.3 Cell Culture and Treatment 
 HeLa (cervical carcinoma) and Jurkat (T-cell lymphoma) cell lines were 
purchased from the American Type Cell Culture (ATCC) (Rockville, MD, USA). 
The cells were maintained in DMEM (HeLa) or RPMI 1640 (Jurkat), 
supplemented with 10% FBS, 100 mg/L streptomycin and penicillin 100 IU/mL at 
37 °C in a humidified atmosphere of 5% CO2. To ensure logarithmic growth, cells 
were subcultured every two days. Stock solutions (50 mM) of purified compounds 
in DMSO were stored in the dark at 4 °C. Appropriate dilutions were prepared in 
culture medium immediately prior to use. In all experiments, the final 
concentration of DMSO did not exceed 0.15% (v/v).  
4.3.4 Cell Viability and Cell Cycle 
 Cells were seeded in 96-well plates and incubated for 48 h in the absence 
(vehicle only) and in the presence of different concentrations of compounds (1 – 
60 µM) and etoposide as positive control. The day before treatments, cells were 
seeded at a cell density of 1×10
4 
cells/well. The number of viable cells was 
quantified by MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide]) assay. Absorption at 550 nm for each well was assessed using a 
microplate reader (LabSystems, Vienna, VA, USA). In some experiments cell 
viability was also checked by Trypan Blue exclusion assay using a Bürker 
counting chamber. Half maximal inhibitory concentration (IC50) values were 
calculated from cell viability dose–response curves and defined as the 
concentration resulting in 50% inhibition of cell survival as compared to controls. 
Cell cycle was evaluated by propidium iodide (PI) staining of permeabilized cells, 
according to the available protocol, and flow cytometry (BD FACSCalibur flow 
cytometer, Becton Dickinson, San Jose, CA, USA) (Hernandez et al 2018). Data 





the hypodiploid region and in G0/G1, S and G2/M phases of the cell cycle were 
calculated using the CellQuest and MODFIT software, respectively.   
4.3.5 Western Blot Analyses 
 Cell whole lysates (HeLa) for immunoblot analysis were prepared according to 
the standard protocol. Protein concentration was determined by DC Protein Assay 
(Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as a standard. 
Proteins were fractionated on SDS-PAGE, transferred into nitrocellulose 
membranes, and immunoblotted with the appropriate primary antibody. Signals 
were visualized with the appropriate horseradish peroxidase-conjugated secondary 
antibody and enhanced chemiluminescence (Amersham Biosciences-GE 
Healthcare, NY, USA). Densitometry of bands was performed with ImageJ 
software. 
4.3.6  Statistical Analysis 
 Data reported are the mean values ± SD from at least three experiments, 
performed in duplicate, showing similar results. Differences between treatment 
groups were analyzed by Student's t-test.  Differences were considered significant 
when p < 0.05. 
4.3.7 Molecular Docking Studies 
 Input Files Preparation for Docking. Protein 3D model of the ATP-bound active 
state of Hsp82, a yeast Hsp90α homologue (PDB code: 2CG9) (Lee et al., 2011) 
was prepared using the Schrödinger Protein Preparation Wizard workflow 
(Maestro version 10.2, 2015). Briefly, water molecules that were found 5 Å or 
more away from heteroatom groups were removed and cap termini were included. 
Additionally, all hydrogen atoms were added, and bond orders were assigned. The 





was built with Maestro‘s Build Panel (Maestro version 10.2, 2015) and 
subsequently processed with LigPrep (LigPrep version 3.4, 2015) in order to 
generate all the possible tautomers and protonation states at a pH of 7.4 ± 1.0; the 
resulting ligands were finally minimized employing the OPLS 2005 force field. 
4.3.8 Induced Fit Docking 
 Binding sites for the initial Glide docking phases (Glide Standard Precision 
Mode) of the Induced Fit Workflow (Induced Fit Docking, 2015; Shermann et al., 
2006a; Sherman et al., 2006b) were calculated on the 2CG9 structure, (Lee et al., 
2011) mapping onto a grid with dimensions of 36 Å (outer box) and 20 Å (inner 
box), centered on residues 628-630, 640–641, 670–675 (Hsp90 residues 
numbering as in the PDB entry 2CG9). Side chains of residues close to the 
docking outputs (within 8.0 Å of ligand poses) were reoriented using Prime 
(Prime version 3.7, Schrödinger 2015), and ligands were redocked into their 
corresponding low energy protein structures (Glide Extra Precision Mode), 
considering inner boxes dimensions of 5.0 Å (outer boxes automatically detected), 
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